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INTRODUCTION 
Transplantation of living tissues is not a new concept. Greek 
mythology presents us with the Chimera in which a goat's body, a 
lion's head and a dragon's tail are joined to form a terrifying mon-
ster. Ancient Indian surgeons made use of local skin flaps for rhino-
plasty, an art which has been practiced in Italy as early as the fif-
teenth century. 
Various transplantation experiments were performed by John 
Hunter in the eighteenth century. However, a systematic approach to 
the study of transplantation biology has only been started during the 
present century when technical progress in the field of surgery 
(Carrel and Guthrie 1905, 1906; Carrel 1908) made it possible to 
transplant a large variety of tissues and organs. 
Unfortunately, surgical problems are not the only obstacles to 
successful transplantation. lt has been known for a long time that 
tissue transplants in which the donor is also the recipient (autografts) 
or transplants between animals of the same inbred strain (isografts) 
will survive. Without complications this also applies to grafts between 
identical twins. On the other hand, transplants between two random-
ly chosen individuals of the same species called homografts or allo-
grafts, behave like autografts for a few days only, after which pro-
gressive damage occurs, leading to loss of function and destruction of 
the graft. This process, called rejection, is usually complete within a 
few weeks following transplantation and is invariably accompanied 
by infiltration with inflammatory cells, predominantly of the mono-
nuclear type. In transplants exchanged between members of different 
species (heterografts, syn. xenografts), a much more violent and 
rapid rejection may take place. 
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The immunological nature of the rejection process is clearly de-
monstrated by the "second-set phenomenon". After rejection of an 
allograft, a second transplant from the same donor will be rejected 
by the recipient in an accelerated fashion while a second transplant 
from another donor will survive for the same period of time as the 
first graft. This may be compared to the accelerated and specific 
response of an animal that has been immunized on subsequent expo-
sure to the sensitizing antigen. 
Being able to distinguish between "self' and "non-self', the body 
can recognize and react specifically against foreign antigens. Thus the 
process of graft rejection is part of a normal and essentially useful 
defense mechanism of the body against all kinds of foreign sub-
stances including microorganisms. It is for this reason, that in addi-
tion to its great practical importance for surgery, investigation of the 
immune response leading to rejection is also of fundamental biologi-
cal interest. 
Skin grafting experiments have contributed largely to our know-
ledge of transplantation biology. Special mention in this respect 
should be made of the work by Medawar (1944, 1945, 1958), 
leading to the formulation of the basic rules of transplantation. At 
present, our knowledge in the various fields of transplantation is ex-
panding rapidly. Yet, while surgical problems are not a limiting fac-
tor any more to clinical application, insufficient understanding of the 
rejection process and of the ways to prevent it is still responsible for 
a considerable failure percentage. 
An ever growing number of papers has been published during the 
past years on transplantation and related topics. Several review arti-
cles and books covering these subjects being available, it seems un-
necessary to make an attempt at reviewing exhaustively the current 
state of our knowledge. For this reason only some of the subjects, 
pertinent to our experiments, will be discussed briefly in the fol-
lowing pages. The reader is referred to the following references for 
detailed information on: 
Immunological aspects of tissue- and organ transplantation: 
Amos, !968; Ramseier, 1969; Russell and Monaco, 1965. 
Bone marrow transplantation: 
van Bekkum and de Vries, 1967; Mathe et aL, !965. 
Experimental and clinical renal transplantation: 
Caine, 1967; Hume, 1967; Largiader, 1966; Rapaport and 
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Dausset, 1968; Starzl, 1964. 
Pathology of human renal transplants: 
Porter, 1966a,b; Shorter and Hallenbeck, 1968. 
Chemical immunosuppression: 
Arnie!, 1967; Berenbaum, 1965; Lardiadi:r, 1968. 
Antilymphocyte serum: 
van Bekkum, 1969; Ciba Foundation study group, 1967; 
James, 1969; Pichlmayr, 1967. 
Latest developments in transplantation research: 
Advance in Transplantation. Proceedings of the First Interna-
tional Congress of the Transplantation Society, 1968; 
Proceedings of the Second International Congress of the 
Transplantation Society, 1969. 
Genetic factors 
Antigenic substances, present in donor tissues but absent in the 
host, give rise to allograft rejection. These substances are called histo-
compatibility antigens and they are genetically determined. Exten-
sive studies in highly inbred strains of mice have demonstrated the 
existence of at least 15 histocompatibility loci on the chromosomes, 
which act independently while the corresponding antigens vary in 
strength. Thus skin grafts between strains of mice that differ at the 
strong H2 locus will be rejected in a much shorter time than grafts 
between strains that differ only at one of the weaker loci. This strong 
H2 system in the mouse received much interest and it proved to be 
very complex, at least 18 alleles occurring at this locus (Snell and 
Stimpfling, 1966). From the independent actions of the histo-
compatibility genes it follows that no rejection will occur if the reci-
pient possesses all the dominant genes of the donor. A system similar 
to that in mice, has been found in other animals e.g. in the rat, and 
aiso in man. In human renal transplantation the effect of genetic fac-
tors has been demonstrated by the much higher incidence of success-
ful grafts when related donors are used as compared to the signifi-
cantly poorer results when donor and recipient are unrelated 
(Seventh Report of the Human Kidney Transplant Registry, 1969). 
Transplant characteristics and the recipient site 
Homografts are rejected by a process requiring sensitization of 
the host. Transplantation antigens are present in all the tissues of an 
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individual and hence any organ or piece of tissue can induce homo-
graft immunity. However, the effectiveness with which different 
grafts do so may vary, depending on a number of factors. Organiza-
tion of the graft is such a factor: it is known that sensitization re-
sulting from injection of living dissociated cells is of a much shorter 
duration than sensitization from a whole organ graft. The quantity of 
antigen .available for sensitization is an important factor and, al-
though little is known for organ grafts in this respect, it has been 
demonstrated for skin that massive allografts and xenografts survive 
longer than small ones (Ballantyne et aL, 1969). The route of admini-
stration of the antigen is also important. In general the intravenous 
and subcutaneous routes are known to be much less effective in pro-
ducing a state of immunity than are the intradermal and intraperito-
neal routes. Thus, the site of a given transplant in the recipient and 
the nature of its connections to the host can affect the duration of 
graft survival. Therefore, it is reasonable to expect that grafts of skin 
and grafts of kidney will behave differently. A skin allograft is com-
parable to an intradermal injection of antigen. Soon after grafting, 
large lymphoid cells have been found to appear in the lymph nodes 
draining the graft site and it has indeed been demonstrated that ef-
fective sensitization by a skin graft depends on adequate lymphatic 
drainage (Barker and Billingham, 1967). In the case of a whole kid-
ney graft, sensitization of the host will occur by way of the venous 
route, while regional lymph nodes are not particularly involved. The 
importance of the recipient site is further illustrated by the occurren-
ce of several privileged sites, where a defect in the afferent or the 
efferent pathway of the host's immune response appears to be re-
sponsible for a permanent survival of allografts and even xenografts. 
Examples of privileged sites are the cheeck pouch of normal, unsensi-
tized hamsters and the anterior chamber of the eye. In the latter case 
vascularization of the graft will be accompanied by rejection, a phe-
nomenon which has also been observed in corneal grafts. Incidental-
ly, pregnancy can also be considered as an allograft that is normally 
exempt from rejection. 
Other differences between transplants of skin and kidney can be 
thought to play a role. The kidney graft is provided with an adequate 
blood circulation from the start, while nutrition of the skin depends 
on the development of anastomoses of small vascular and lymphatic 
channels between host and donor tissue. Specific factors inherent to 
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the specific function of the organ involved could also contribute to 
differences in survival. The clearance function of the kidney could 
promote damage to the glomeruli by exposing them to high concen-
trations of macromolecules, e.g. antibodies or immune complexes. 
On the other hand, impairment of clearance function may result in 
uremia and raised blood levels of immunosuppressive drugs, both 
known to promote graft survival. Generally speaking, acceptance of 
skin grafts is more difficult to achieve than acceptance of kidney 
grafts. It is known even that a recipient can reject a skin graft while a 
kidney from the same donor, transplanted at the same time, conti-
nues to function (White and Hildemann, 1968, 1969; White eta!., 
1969). 
The homograft reaction 
Notwithstanding the overwhelming number of investigations on 
the subject, the whole sequence of events leading to rejection of a 
transplant is still incompletely understood. Strong histocompatibility 
antigens, while evoking the development of transplantation immu-
nity, induce at the same time the formation of humoral antibodies 
(as hemagglutinins, hemolysins, cytotoxins, etc.) which can be de-
tected with relative ease by means of serological tests in vitro. Since 
sensitization with cell-free extracts proved to be feasible, attempts 
have been directed towards establishing the chemical nature of the 
antigens. So far, it has been demonstrated that antigenic activity is 
mainly associated with lipoprotein structures on cell surface mem-
branes. To study the effects of antigen administration it is important 
to isolate these substances as pure antigens. 
There is no agreement about whether histocompatibility antigens 
are released from the graft site as free antigens or as cell-bound anti-
gens. Little is known about how antigens are recognized and pro-
cessed to give rise to proliferation of immunocompetent cells. Appa-
rently, both the antigen reactive cell and the effector cell reside in 
the fraction of small lymphocytes. 
It is well known that after antigenic stimulation a certain propor-
tion of the small lymphocytes undergoes transformation into large, 
pyroninophilic, blast-like cells. It is probable that this change results 
from interaction with antigen and morphologically it is the earliest 
manifestation of the immune reaction. Transformed cells can be 
readily demonstrated in the lymph nodes draining the site of a skin 
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homograft. It is thought that the production of immunologically ac-
tive lymphocytes represents the ultimate result of this reaction. In 
case of a kidney graft, lymphatic drainage is initially lacking. How-
ever, there is experimental evidence to suggest that in such a vascu-
larized graft sensitization of blood lymphocytes can occur (Strober 
and Gowans, 1965). On the other hand, in the venous outflow from 
renal grafts, free antigens have been demonstrated as well (Najarian 
et a!., 1966). 
For a long time the invariable presence of large numbers of 
lymphoid cells in first-set allografts during rejection and the fmding 
that allograft immunity could be passively transferred by means of 
lymphoid cells, serum being ineffective in this respect, were the main 
arguments to consider rejection as a cellular immune reaction. More-
over, it has been demonstrated that specifically sensitized lymphoid 
cells can directly destroy allogeneic and xenogeneic target cells in 
vitro (Ginsburg et a!., 1969). Nevertheless, the question remains, 
whether or not only a proportion of the cells infiltrating an allograft 
is capable of a specific action, the rest being secondarily attracted by 
the damaged tissue. 
Morphological lymph node changes associated with the develop-
ment of cellular immunity can be distinguished from those found in 
humoral antibody formation (Turk and Oort, 1967). In the latter, 
development of germinal centres and the presence of plasma cells are 
prominent signs. Lymph node changes observed in experimental in-
duction of a cellular immune response resemble closely those fouml 
after skin grafting. The changes consist of a blast-cell response in the 
paracortical area of the draining lymph nodes. This once more points 
to the importance of cellular mechanisms in the rejection of a skin 
graft. For kidney grafts however, this is much more difficult to de-
monstrate. There is no doubt that lymphoid cells play an important 
role in the rejection of kidney grafts as well, but recent investigations 
have shown that circulating antibodies directed specifically against 
donor kidney tissue and present within a week after transplantation, 
can induce lesions, comparable to those found in allografts in the 
course of their rejection (Clark et a!., 1968). Of great practical im-
portance in this respect is the role played by preformed antibody in a 
number of clinically known cases of early transplant rejection called 
"hyperacute rejection". Failure to demonstrate the significance of 
humoral antibody in earlier experiments might have been due to in-
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sufficient sensitivity of the techniques used and to disappearance of 
antibody from the circulation as a result of cross reaction with the 
host's own tissues and absorption by the graft. 
Prevention and modification of the immune reaction 
Methods, used to prevent or to modify the immune reaction in 
experimental and clinical renal transplantation include such diverse 
procedures as histocompatibility matching, induction of tolerance, 
splenectomy, thymectomy, lymphoid depletion by chronic thoracic 
duct drainage, extracorporeal irradiation of the blood, irradiation of 
either the whole body or the graft and administration of various che-
mical agents and antilymphocyte serum (ALS). Of these, whole body 
irradiation and thymectomy are no longer in current clinical use, 
while extracorporeal irradiation of the blood and lymphoid depletion 
by thoracic duct fistula are still largely in the clinical experimental 
stage. 
The induction of tolerance is of particular interest to the experi-
mentalist. Specific immunological tolerance (Billingham et al., 1953, 
1954, 1955) can be induced in neonatal animals by exposing them to 
large doses of an antigen before they have developed the capacity to 
react against it. The animals thereby permanently lose the ability to 
react against this particular antigen while the ability to react against 
other antigens is not impaired. It has been demonstrated since, that, 
under certain experimental conditions, tolerance can be induced in 
adult animals as well by prolonged treatment with large doses of 
soluble antigen. For insoluble antigens, the matter is less clear, while 
injection of lymphoid cells has been either ineffective in this respect 
or has resulted in chimerism. Sensitization to homografts is probably 
due to a mixture of antigens, which have not yet been isolated and 
identified as being important as sensitizing antigens. However, induc-
tion of tolerance appears to be a very promising way to alter the 
immune reaction against human transplants in the future. 
Of great practical importance is the technique of histocompatibi-
lity testing, which is now used with increasing frequency in clinical 
transplantation to prevent a strong immune reaction. Using the fact 
that most histocompatibility antigens are present on the leucocytes, 
typing procedures have been developed which permit selection of a 
recipient possessing all known histocompatibility antigens, or all the 
supposedly strong ones, present in the donor (Ceppelini et al., 1967; 
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Dausset et a!., 1967; Payne et a!., 1967; van Rood et a!., 1967; 
Terasaki et a!., 1967). In this way, it is possible to select the best 
compatible donor-recipient combination, resulting in a relatively 
weak immune reaction after transplantation which can be suppressed 
readily with immunosuppressive therapy. 
At present, the basic therapy in the management of clinical renal 
transplantation consists of administration of the approved drug 
Imuran (azathioprine) together with corticosteroids, combined 
during rejection episodes with actinomycin C. Local irradiation of 
the graft is sometimes used prophylactically or in treatment of a 
rejection crisis, its action being probably due to destruction of 
lymphocytes in the graft (Tinbergen, 1968). In some centres anti-
lymphocyte serum has been used in addition to chemical agents. 
Drugs known to suppress the immune response have several 
mechanisms of action. They have in common the capacity to inter-
fere with the production of immunocompetent cells and/or antibody 
and hence an increased risk of infectious complications is inherent to 
their use especially with the high doses given in treatment of rejec-
tion crises. The antimetabolite lmuran (azathioprine) is an imidazolyl 
derivative of 6-mercaptopurine. It has the same immunosuppressive 
properties as 6-mercaptopurine, but it is less toxic. However, liver 
damage and bone marrow depression are known complications of 
Imuran therapy. Corticosteroids are effective if given in high doses 
with the risk of side effects. 
The immunosuppressive action of heterologous antibodies, 
directed against lymphocytes has been first demonstrated in 1963 
(Woodruff and Anderson, 1963, 1964). It appeared that ALS was 
able not only to affect the afferent and efferent pathways of the 
immune response, but also to erase immunological memory as evi-
denced by suppression of the second-set reaction. The initial concept 
that immunosuppressive action resulted from a direct toxic influence 
upon lymphocytes is not an entirely adequate explanation since it 
was shown that the lymphopenia resulting from ALS administration 
is not a prerequisite for immunosuppressive activity. However, it is 
now generally accepted that only a certain fraction of the peripheral 
lymphocytes is specifically interfered with. Alternative theories to 
explain the action of ALS (Levey and Medawar 1966a,b, 1967) 
include competition (blocking of antigen-reactive sites on lympho--
cytes by ALS) and blindfolding (interfering with the recognition of 
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antigen by lymphocytes after ALS treatment). Another hypothesis is 
called sterile activation: in contact with ALS, non-committed 
lymphocytes are transformed into blast cells, thereby losing their 
capacity to develop immune competence towards other antigens. 
Whatever its action, it has been shown in various animal species, and 
in man, that ALS can be a very potent immunosuppressive agent. Un-
fortunately, clinical use of ALS is hampered by the fact that, until 
recently, no reliable in vitro method was available to test its immuno-
suppressive potency. Moreover, experiments on ALS have been per-
formed with sera prepared in various species, using cells from diffe-
rent sources as the antigen, which were administered along various 
routes according to different immunization schedules. As could be 
anticipated the resulting sera showed wide variation in immuno-
suppressive potency, and in toxicity (especially towards erythrocytes 
and thrombocytes). All this, of course, makes it difficult to compare 
experimental results. Particularly important from the clinician's 
point of view is the fact that foreign proteins are introduced by ALS 
treatment with the associated dangers of anaphylaxis and serum sick-
ness, while the formation of antibodies against the agent itself will 
also lead to loss of immi.mosuppressive potency. Some of the risks of 
ALS treatment, as its hemolytic action and the development of 
thrombocytopenia can be reduced by using the purified lgG fraction 
(ALG) which represents the active principle and by absorption. How-
ever, toxicity may not be ruled out completely by these procedures. 
Contradictory results have been reported about the effect of purifica-
tion of ALS in preventing hypersensitivity reactions (Cohen et al., 
1970; Lindquist et al., 1969). In human transplantation, the advan-
tage of ALG therapy has been that doses of other immunosuppres-
sive drugs could be reduced, thus avoiding their side effects (Starzl et 
al., 1969). 
Rationale for the experiments 
In the Seventh Report of the Human Kidney Transplant Registry 
(1969), based on 2347 human kidney transplantations, it is esti-
mated that kidneys from related living donors have a !-year survival 
of 87% and a 2-years survival of 77% while kidneys from cadaver 
donors have a !-year survival of 42% and a 2-year survival of 40%. 
Probably, figures for patient survival are much higher, because of the 
common practice to dialyse and retransplant a patient after 
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transplant failure. Recent results showed significant improvement 
over those before 1966. However impressive these results are, as com-
pared to the situation during the early days of human renal trans-
plantation, it is evident that there is much to be desired. Apart from 
the still considerable percentage of failure, it is obvious that the 
ethical objections to and the limited availability of kidneys from re-
lated living donors, make the use of cadaver donors preferable to the 
use of living donors. However, apart from improvement in storage 
techniques and selection methods, this would require the develop-
ment of better and more specific immunosuppressive methods. Be-
sides, experience in renal transplantation is now of great importance 
in management of other organ transplants, failure of which might 
present much more urgent problems than failure of a kidney graft. 
For instance, it is now realized that immunosuppression as used in 
renal transplantation is not equally effective in heart transplantation 
(van Bekkum eta!., 1969, 1970; Second World Symposium on Heart 
Transplantation, 1969). This underlines the importance of continued 
studies on the action of immunosuppressive agents. 
The experiments which will be discussed below are concerned 
with immunosuppression: Imuran and Prednisolone as the agents 
which are universally used in clinical practice and ALG (antilympho-
cyte globulin) which is now at the centre of interest, both in experi-
mental and in clinical transplantation, have been compared in a con-
trolled trial. It is known that both the incidence and the severity of 
rejection crises decrease when an allograft has resided in the host for 
some time. Therefore we investigated the action of immunosuppres-
sive agents during a restricted period early after transplantation, 
which period is apparently of crucial importance. Because of qualita-
tive and quantitative differences between grafts of skin and kidney, 
as discussed above, skin grafts were considered inadequate for the 
present investigation. Sofar, renal transplantation experiments have 
been performed mainly in larger animals such as dogs. Results from 
these experiments are difficult to compare for several reasons: most 
series produced are small and there is considerable variation in tech-
nique, maintenance and immunosuppressive methods used, as well as 
drug doses given. Most important, however, is the variation in histo-
compatibility difference between randomly selected non-inbred 
members of a species, which makes the unmodified rejection time 
greatly variable. These drawbacks, which also operate in human 
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transplantation, are largely overcome by the use of inbred strains of 
small laboratory animals now available. Since a technique for ortho-
topic renal transplantation in the rat* has been developed it is pos-
sible to produce large series of allogeneic transplantations in which 
rejection time is ahnost constant while isogeneic transplantations can 
be performed as controls. Moreover, rats are relatively cheap and 
easy to maintain. A disadvantage is the difficulty of the operation 
technique causing a high percentage of technical failures. Several 
reports by now have demonstrated the usefulness of the rat model 
system for renal transplantation studies (Feldman and Lee, 1967; 
Feldman et aL, 1968; French and Batchelor, 1969; Gardner et aL, 
1968; Guttmann et al., 1967a,b, 1968, 1969a,b,c,d; Guttmann and 
Lindquist, 1969; Hollander, 1970; Lindquist et al., 1968a,b,c; 
Murray, 1969; Sakai et al., 1968, 1969; Salaman, 1968; Spong et aL, 
1968; Stuart et aL, 1968a,b; Taguchi et al., 1968; Tinbergen, 1968; 
White et al., 1969; White and Hildemann, 1968, 1969). The tech-
nique for orthotopic renal transplantation in the rat as described by 
Fisher and Lee (1965) has been introduced into the Radiobiological 
Institute of the Organization for Health Research TNO in 1966 by 
Tinbergen who studied the effects of continuous treatment with 
some immunosuppressive agents on graft survival (Tinbergen, 1968). 
He observed marked prolongation of survival time by treatment with 
Imuran. Treatment with either Prednisolone or local irradiation of 
the graft was less effective. Mean survival time in 43 untreated allo-
grafts was 12 days (9 - 24 days) if one exceptional case of long survi-
val (55 days) is omitted. The present study can be regarded as a con-
tinuation of this work, with special emphasis on a more precise evalu-
ation of the condition of the grafted kidney under immunosuppres-
sive treatment. The investigation comprises the following: groups of 
allografted rats, treated for no longer than 3 weeks after transplanta-
tion with various doses and combinations of lmuran, Prednisolone 
and ALG were compared with untreated allografted and isografted 
rats with respect to 50-day survival, renal function and transplant his-
tology. The period of 3 weeks after transplantation for immuno-
suppressive treatment was chosen because the majority of rejection 
crises was known to occur during that period. 
* The term orthotopic transplantation is used as opposite to transplantation in the neck, 
performed in earlier experimental work, and does not imply that the position of the 
grafted kidney is really orthotopic. 
2! 
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The purpose of the present investigation is mainly: 
to evaluate the usefulness of some serial function tests in assessing 
the condition of a grafted kidney in the rat as related to 50-day 
survival and microscopical appearance of the graft; 
to compare under controlled conditions the efficacy of immuno-
suppression obtained with different regimens, especially with 
regard to ALG; 
to study the effect of short-term immunosuppressive therapy on 
renal graft rejection. 
MATERIALS AND METHODS 
Experimental animals 
The rats used in the experiments were derived from 2 inbred 
strains, Wag/Rij and BN/Bi, maintained at the Radiobiological Insti-
tute of the Organization for Health Research TNO Rijswijk. Since 
1960 both strains were bred under specific pathogen free conditions 
by rearing of young animals in isolated quarters after delivery by 
cesarean section of the first few individuals. The Wag/Rij strain is an 
inbred Wistar albino strain, originally obtained from Glaxo Laborato-
ries, Greenford, Middlesex, England and bred by brother x sister 
matings for 29 generations since 1953 at Rijswijk. Histocompatibility 
between members of this strain was frequently confirmed by recipro-
cal skin grafting, showing permanent takes in 100%. Wag/Rij males, 
5-8 months of age and ranging in weight from 250- 350 g were 
recipients of kidney grafts as well as kidney donors in the isogeneic 
transplantations. The other inbred strain, BN/Bi, was supplied in 
1963 by Microbiological Associates Inc., Washington and also main-
tained by brother x sister mating. This strain was started in 1958 by 
Silvers and Billingham from a brown mutation obtained from King 
and Aptekman. Subsequent inbreeding has been directed towards 
developing histocompatibility resulting in 100% skin graft accep-
tance. Males from the BN/Bi strain, aged 3 - 6 months and weighing 
200 - 300 g, were used as donors of kidney allografts. BN/Bi and 
Wag/Rij rats differv at the strong H-1 histocompatibility locus (Stark 
and Kl:en, 1969; Stark et aL, 1969). Skin grafts between the two 
strains are consistently rejected within 10 - 12 days. 
Rats were maintained individually or in groups of 2 in auto-
clavable, transparent polycarbonate cages. Temperature and 
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humidity of the room were kept constant at 21 oc and 65% respec-
tively. Saw dust, used as bedding material, was changed twice 
weekly. Tap water and food pellets (Hope Farms, Holland, crude 
protein content 25%) were supplied at libitum. To prevent spread of 
bacteria the drinking water was acidified up to pH 3 by adding HCI. 
Cages were sterilized twice weekly by steam heating for 20 min. at 
120°C, while drinking bottles and tubes were sterilized daily for I 
hour at 120°C by dry heat. 
Surgical technique 
The microvascular technique for orthotopic renal transplantation 
in the rat as described by Fisher and Lee (1965) was used. The 
method has been slightly modified since Tinbergen introduced it into 
the Radiobiological Institute in 1966 (Tinbergen, 1968). Briefly, the 
procedure is as follows. After an intraperitoneal dose of Nembutal 
(Abbott, 10% solution in saline) containing 4 mg of Na pentobarbi-
tal/! 00 g body weight, duration and depth of narcosis was easily con-
trolled by open drop ether administration during operation. After 
opening the abdomen of the donor animal the right kidney, together 
with its renal artery and vein are mobilized. The ureter is then freed 
and transsected near the bladder. After injection of Heparin 
1500 I.U. (Vitrum, Stockholm) into the aorta, the kidney is removed 
from the body in such a way that elliptical cuffs of aorta and vena 
cava are left at the end of the renal vessels. The kidney is then kept 
at 40C in Tyrode solution. Donor kidneys showing double arteries, 
evident hydronephrosis or dilatation of the ureter, are discarded. The 
aorta and vena cava of the recipient animal are clamped together 
below the renal vessels with a Satinsky-like curved clamp. The 
clamping is done in such a way as to isolate part of the vessel from 
the circulation. Small elliptical openings are then made in this part, 
to which the cuffs of the transplant vessels are anastomosed (fig.!). 
Bleeding at the site of anastomosis after release of the vascular clamp 
is controlled by pressure with a piece of folded gauze for 20 - 40 
seconds. The total period of renal ischemia ranged between 20 and 
40 minutes, the average being 36 minutes. 
A small opening is then cut in the mid-dorsal part of the bladder. 
The ureter tip is taken and drawn into the bladder through this ope-
ning by means of a stitch through the low-dorsal part of the bladder 
wall. After the ureter is secured by this stitch, the bladder opening is 
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Fig.l Anastomosis of the renal vessels. Cuffs of aorta and vena cava,.lf::ft at the end of the 
renal artery and vein are sutured to elliptical openings in the recipient aorta and vena 
cava. The first stitches of the continuous sutures at both sides of the cuffs are 
shown. Part of the aorta and vena cava are clamped off from the circulation. In this 
case an accessory clamp has been used (the left one in the picture). The ureter is 
still loose. 
closed. To facilitate differentiation between technical failure and re-
jection of the transplant, both kidneys of the recipient are fmally 
removed. Atraumatic silk (Ethicon, no. 7-0) is used for the anasto-
moses of ureter and vessels. In general the whole procedure is com-
pleted within 2 hours. 
Seven days after transplantation an open wedge biopsy was taken 
from the mid-lateral part of the transplanted kidney under ether 
anaesthesia. 
Antibiotic treatment 
All animals (unilaterally nephrectomized controls included) were 
treated with antibiotics for 8 days after operation according to a 
scheme that proved to be most effective in previous experiments. 
Penicillin and streptomycin were given i.m. on day 0, 1, 7 and 8, 
10.000 LU. and 10 mg resp. (Retromypen S, Mycofarm, Delft, Hol-
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land) and chloramphenicol 10 mg i.m. daily on day 2, 3, 4, 5 and 6 
(Gloveticol, Mycofarm, Delft, Holland). In no case were antibiotics 
given beyond day 8. 
Immunosuppressive treatment 
Imuran, Prednisolone and ALGin various doses and combinations 
were used as immunosuppressive agents. In all cases, treatment was 
discontinued, 3 weeks after operation. 
Imuran* (azathioprine) solutions were prepared as follows: 500 mg 
of Imuran was suspended in 10 ml of saline, then, while stirring and 
drop wise, 1.81 ml of a 1 N NaOH solution was added to pH 9. After 
adding saline to a total volume of 50 ml, pH was brought to 8, if 
necessary, with 1 N HCI. Solutions were used for no longer than one 
week. Imuran either 2 or 4 mg/kg body weight was administered 
daily intraperitoneally for 3 weeks after operation. One group of rats 
was treated for 4 weeks with Imuran 2 mg/kg body weight, starting 1 
week before transplantation. 
Prednisolone sodium succinate (Organon, Oss, Holland) was used as a 
2 mg/ml solution in distilled water and prepared just before use. Rats 
treated· with Prednisolone received a daily dose of 4 mg/kg body 
weight subcutaneously for 3 weeks, starting the day after operation. 
Antilymphocyte globulin** (rabbit anti-rat thymocyte serum, con-
taining highly purified IgG after purification) was given in 4 weekly 
doses of 19 mg lgG/animal subcutaneously, the first dose being admi-
nistered I week before operation. 
ALS was produced as shown schematically in fig.2. Both male 
and female rabbits of 7 - I 0 kg. randomly bred and shown to be 
without naturally occurring toxins for rat lymphocytes were injected 
subcutaneously every I 0 days with thymocytes. obtained from 6 
week old Wag/Rij rats and suspended in Tyrode solution. After 4 
doses of I o9 thymocytes. I 00 ml of blood was taken from the ear 
vein. A booster dose of thymocytes was given I 0 days later and after 
a further I 0 days the rabbits were bled out. Serum from tap I and 
tap II were pooled, yielding for subsequent purification a total of 
* Imuran was made available by Burroughs WeUcome, London, through the courtesy of Dr. 
D.A. Long. 
** Purification of ALS, as described, was kindly performed by :rv.fiss A.W.M. Appelman and 
· Mrs. M.A. Graver-van der Vring. 
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Fig.2 Immunization schedule for preparation of rabbit anti-rat thymocyte serum 
(ALS). Serum from tap I and tap II were pooled for isolation of the IgG fraction. 
± 150 ml serum per rabbit in which 'Y-globulin constituted 12% of 
the total protein, as determined by electrophoresis. To precipitate 
the globulin fraction, (NH4)2so4 was added to the serum to a fmal 
concentration of 45%. The precipitate was suspended in distilled 
water and dialyzed for 24 hours against running tap water and sub-
sequently for 36 hours against 0.01 M phosphate buffer in 0.82% 
NaCI, pH 7 .4. The dialysate was then passed through a column of 
DEAE Sephadex A-50 anion-exchanger (Pharmacia, Uppsala, Swe-
den). The first fractions eluted from the column by the NaCI/phos-
phate buffer contained almost pure IgG, which was checked by elec-
trophoresis on cellulose acetate and by immune electrophoresis. Only 
those fractions containing 97% or more IgG were used. The fmai pre-
parations contained ± 19 mg lgG/mL The whole procedure of purifi-
cation was performed at 4°C to prevent growth of bacteria in the 
serum. Lymphocytotoxic titers of the crude preparations were 
I :2000 (ALGI) and I: 128 (ALG II). 
In the skin grafting experiments for testing ALS, best results were 
obtained if treatment was started before transplantation: 4 weekly 
doses of 12.5 mg IgG resulted in mean skin graft survival times of 
116 days for ALG I (17, 18, 20, 205 and 230 days) and 66 days for 
ALG II (18, 73, 83 and 90 days). 
Histological technique 
Kidney biopsies taken on day 7 after transplantation and material 
obtained at autopsy were available for microscopical examination. In 
addition to the kidney, ureter and bladder, heart, lung, liver, 
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pancreas, gut, thymus, spleen, abdominal lymph node and sternum 
were studied. The tissues were fixed in 4% buffered formalin for a 
minimal time of 24 hours, then processed in an Autotechnicon 2A 
(TechniconCompany, Chauncey, New York, U.S.A.) and imbedded 
in paraffm. Sections of 5 fJ. were cut and routinely stained with 
Hematoxylin-Phloxin-Saffron (H.P.S.). In some cases sections of kid-
ney tissue were cut at I fJ. and stained with H.P.S., periodic acid-
Schiff (P.A.S.) and periodic acid silver methenamine (P.A.S.M.). 
Transplant function* 
Transplant function was assessed from 1 week before transplanta-
tion onward by serial determination of the following parameters. 
1) Body weight, as a general index of the health of the animal, was 
determined twice weekly. 
2) Hematocrit values, reflecting possible toxic effects of immuno-
suppression and uremia, were also determined twice weekly. 
After keeping the rats for 10 minutes under an infra-red lamp, 
blood samples were obtained by cutting the tip of their tails. 
Heparinized microhematocrit tubes containing 0.075 ml of blood 
approximately, were centrifuged for 5 minutes at 11.500 r.p.m. 
before reading (International Equipment Company, Boston, 
Mass., U.S.A.). In 200 untreated rats a normal hematocrit value 
of 50% was found before transplantation, with a standard 
deviation of 3.6%. Standard deviation of the differences between 
duplicate measurements (60 pairs) was 1.3%. 
3) Blood urea (B.U.) was measured twice weekly to assess the excre-
tory capacity of the kidney, using the serum after hematocrit 
reading. Samples of 0.02 ml of serum were diluted to a volume of 
1.0 ml with 0.9% NaCL Urea concentration was determined on a 
Technicon autoanalyzer (diacetyl monoxime reaction)**. Mean 
normal value in 200 rats was 60 mg%, standard deviation 23%. In 
I 00 duplicate determinations, standard deviation of the diffe-
rences was 7%. 
* Although body weight, blood pressure and hematocrit value are not direct parameters of 
renal function, the listed determinations will be referred to as transplant function for 
convenience. 
** Blood urea determinations were performed at the Analytical Centre of the Central Labo--
ratory ofTNO? Delft (Head Drs. W. Brouwer). 
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4) Urine osmolality reflecting the concentrating capacity of the kid-
ney was measured twice weekly in freshly voided specimens of 
morning urine, obtained between 9 and I 0 a.m. If voiding did not 
occur spontaneously, it could be induced in most cases by 
squeezing the taiL Covering the test tubes with parafilm pre-
vented evaporation. Osmolality values were determined in 0.2 ml 
samples of urine using a freezing point osmometer (Advanced In-
struments, Inc., Mass., U.S.A., model31 La). Reading was always 
done in duplicate. A mean normal value of 2190 milliosmols/kg 
H~O was found (200 samples) with a standard deviation of23%. 
Standard deviation of the differences between duplicate measure-
ments was 1.5% (I 00 pairs). 
5) Urine production per 24 hours was determined once weekly be-
cause of its relationship to urine osmolality in removing a certain 
solute load. Rats were placed in metabolic cages with free access 
to food and water. Mean normal value was 5 ml ( 40 rats) with a 
standard deviation of 30%. 
6) Systolic blood pressure was measured to detect the development 
of hypertension during rejection episodes. Blood pressure deter-
minations (fig.3) were performed every week in unanesthetized 
rats using a modification of the method described by Weinman 
Fig.3 Equipment for blood pressure determination in the rat. For description see text. 
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(Weinman et aL, 1960; Ben-Ziv et aL, 1964). Rats were warmed 
under infra-red lamps for 10- IS minutes to ensure adequate 
blood flow through the tail and tben immobilized in a rat holder 
(l). A metal tubular occluding cuff (2) (7/16" internal diameter, 
E and M Instrument Company Inc., Houston, Texas) connected 
with an ordinary blood pressure manometer (3), was placed 
proximally around the animal's tail. The distal part of the tail was 
passed through a cylindrical opening in a metal box ( 4 ), inside 
which a lamp and a light dependent resistor (LDR) were placed 
on opposite sides of the tail. Blood pulses in the tail, as detected 
by the LDR, were amplified and made visible as a continuous 
wave on an oscilloscope (5). Values for systolic blood pressure 
were read on the manometer after inflating the cuff up to the 
point where tbe waves flattened out to become a straight .line. 
Three successive blood pressure readings, each taken to the 
nearest 5 mm Hg were averaged to yield the final value. It was 
found that, if handled gently, the animals were not excited by the 
procedure. Mean normal value in 100 rats was 125 mm Hg with a 
standard deviation of I 0 mm Hg. Standard deviation of the dif-
ferences between duplicate measurements was 6% (I 00 determi-
nations). 
7) Intravenous pyelography. Rats were sacrified for microscopical 
investigation at 50 or 100 days after transplantation, at which 
time sufficient information on transplant function was expected 
to be available to warrant conclusions. Intravenous pyelography 
was performed immediately before tbe animals were sacrified to 
assess the incidence of anatomical lesions of the urinary tract. 
Water was withheld for 5 hours previously. After anesthesia with 
Nembutal (Abbott, diluted 1 :5 in saline, 5 ml/kg i.p.), each rat 
received a I ml dose of Urografin 76% (Schering A.G., Berlin), 
injected slowly into a tail vein. Rats were then taped on a cassette 
(Kodak 24 x 30 with high definition screen) and roentgenograms 
were obtained at 5, 10 and IS minutes after injection of the con-
trast dye, using a portable roentgentube (Enraf, Delft, Holland, 
focus-film distance 83 em, exposure with 55 kV and 25 rnA 
during 0.16 sec.). 
Statistical evaluation of results 
In the Appendix all averages (x) of the values x obtained in dif-
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ferent groups of rats are given separately for each parameter, to-
gether with the number of animals from which the average was 
derived (n) and with the standard deviation (s) calculated by the for-
mula 
_jz;(x-x)2 
S- l n-
The average values were used to prepare the figures on renal function 
(figs.S - 18). 
Average values obtained during the period from the third to and 
including the seventh post-transplantation week were used for statis-
tical analysis. Thus, l 0 values for weight, hematocrit, blood urea and 
urine osmolality and 5 values for blood pressure and 24-hour urine 
production were available for each group, listed in the Appendix as 
no. 7 - 16 and no. 4- 8, respectively. Two groups in tum were com-
pared for one parameter. Pairs of 2 corresponding average values 
were tested consecutively using the test of Welch (1947) after which 
the t values were used in a combination test (de Jonge, 1964). This 
included the following steps: 
A. 
Welch: xl - x.2 
t= 
vsl: 
") 
s -2 
+--2 
nl n2 
with a number of degrees of freedom: 
3! 
B. Application of the combination test requires that the t value and 
f value found are converted to the standard normal variable Z. In 
order to do so, first a p 1 value is read from a table of Student's t 
values (Documenta Geigy, 1969) and then Z can be found from a 
table of the normal probability integral (Fisher and Yates, 1953, 
Table VIII, in which the symbol Z is expressed as x). A positive 
or negative sign oft is conserved. 
·Instead of using these tables, we have calculated Z directly 
fr.om t and f, using a formula, developed by Wijnans ( 1969) which 
gives a good approximation if f;;;;, 5: 
z = t- 0.588 (t
3 + t) 
2.4195 f + t2 
C. Finally, the number of Z values {k) was combined: 
l:Z 
Zc = {k 
D. From a table of the normal distribution (Fisher and Yates, 1953, 
Table I) it appears that the critical values for Z (= x) at a 1% level 
of significance are ± 2.58. 
Thus whenever treatment groups are reported to be different for 
a certain parameter, it means that the hypothesis, that there are no 
differences between the two groups of means, was rejected after two 
sided testing at a level of significance x = 0.0 I. 
Calculation of statistical significance was performed only in those 
cases which were considered directly relevant to the argument. Re-
sults of statistical evaluation of differences between treatment groups 
is given as a survey in table IV. 
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RESULTS 
General 
Renal transplantation was performed in a total of 282 cases, in-
cluding allogeneic and isogeneic transplantations. During transplan-
tation and within 24 hours thereafter, 85 rats died. Apart from mor-
tality duling anesthesia, the main causes for this early failure were 
bleeding and obstruction at the site of anastomosis of the great blood 
vessels. It was noted that treatment with Imuran, given before opera-
tion, affected this early mortality. As is shown in table I the percen-
tage of failure within 24 hours after transplantation was almost twice 
as high in the group that was pretreated with Imuran in comparison 
to the groups which until then had received either no treatment or 
one dose of ALG. 
Rats, dying during the period of one to fifty days after transplan-
tation, were separated into two groups. The first group comprises 
those rats in which a definite cause of death, such as infection or 
technical failure could be pointed out. They were excluded from the 
experiment. In the second group, no definite cause of death could be 
found, mortality therefore was attributed to rejection of the 
transplant. In the paragraph on renal function, the values of these 
animals have been included in the results obtained with the different 
treatment schedules. 
The kind of complications found in the I 02 rats making up the 
first group are shown in table IL Disconnection of the ureter at the 
site of implantation in the bladder and obstruction of urine flow by 
blood clots or inspissated protein accounted for death in 50% of the 
cases. The incidence of vascular obstruction was rather low. How-
ever, technically unsuccessful anastomoses of the great vessels gener-
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TABLE I 
EFFECT OF PRETREATMENT ON EARLY MORTALITY 
OF ISOGRAFTED AND ALLOGRAFTED RATS 
total mortality within 24 hours 
Treatment no. no. % 
Untreated 165 46 28 
ALG 86 23 27 1x19 mg/rat 
lmuran * 
6x2 mg/kg 31 16 52 
Total 282 85 33 
* Increased early mortality is statistically significant 
(chi square test, p< 0.05) 
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TABLE II 
IDENTIFIED CAUSES OF DEATH IN 102 ISOGRAFTED 
AND ALLOGRAFTED RATS DYING BETWEEN 
1 AND 50 DAYS AFTER TRANSPLANTATION 
Ureter disconnected 30 
Ureter obstructed 21 
Vascular anastomosis obstructed 17 
Infection 11 
Accidents 16 
Other technical failure 7 
(death before dey 5) 
ally caused massive hemorrhage and death within 24 hours after 
operation. Infection was regarded as the cause of death only in cases 
of extensive pyelonephritis and/or septichaemia. Accidents included 
death from bleeding or narcosis at biopsy, as well as some cases dying 
from injection injury during intraperitoneal administration of 
Imuran. As rats after bilateral nephrectomy can live for 4- 5 days, 
the animals dying before day 5 were considered to be technical 
failures, although in these case no cause of death could be estab-
lished. 
The incidence of complications and of rejection during the period 
of one to fifty days after transplantation is shown in fig.4. The upper 
2 graphs show that death from allograft rejection in treated and un-
treated rats occurred during the same period. Note that deaths from 
rejection did not occur from day 22 onward, when immunosuppres-
sive treatment was discontinued. The 2 lower graphs in fig.4 show 
the incidence of complications in allografted and isografted rats. It is 
clear that up to the eleventh day, the mortality pattern was very 
much the same in both groups, while thereafter, complications con-
tinued to occur in the allografts and not in the isografts. The ex-
planation of this is that infection as a cause of death was found al-
most exclusively among allografted animals following treatment with 
various immunosuppressive drugs. In 8 out of ll allografted rats in-
fection was the cause of death after the eleventh day, which could be 
attributed to the immunosuppressive treatment and for that reason 
could hardly be avoided. 
After exclusion of the 85 rats dying during the first 24 hours 
after transplantation and of the I 02 rats dying from complications a 
total number of 95 transplantations remained for evaluation. 
Table Ill shows the various treatment groups together with the 
survival data at 50 days after transplantation. Survival in the iso-
grafted group was 100%. Quite unexpectedly, one of the allografted 
rats survived for 50 days without treatment. In the 3 groups treated 
with Imuran alone, less than 50% of the rats were alive at 50 days. 
Survival is appreciably higher in the last 6 groups, treated with 
lmuran and Prednisolone, with ALG alone and with a combination 
of ALG and lmuran. Considerable differences were noted in effecti-
veness between the two batches of ALG (ALG I and ALG II) which 
justifies a separate presentation of the groups treated with ALG I 
and IL 
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Flg..4 Mortality during the first 50 days after transplantation. The incidence of death from 
graft rejection and from various complications have been compared. 
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TABLE Ill 
TREATMENT AND 50-DAY SURVIVAL OF 95 \SO GRAFTED 
AND ALLOGRAFTED RATS 
TREATMENT 50-DAY SURVIVAL 
surviving no. 
total no. 
percentage 
I so grafted Untreated 
rots 10/10 100 
Untreated 1/11 9 
lmuron* 4 ms/kg 3/9 33 
lmuran ... 2 mg/kg 6/13 46 
lmuron 2 mg/kg 4/10 40 pretreated 0 
lmuron* 
+ 
2 m g/kg 8/10 80 
+Prednisolone 4 mg/kg 
Allogrofted 
rats IX ALG 19 mg/rot 7/7 100 
ALG X 19 mg/rot 5/7 71 II 
ALG X 19 mg/rat 
+ lmuron* 4 mg/kg 4/5 80 
ALG 1\x 19 mg/rot 3/5 60 + lmuron * 4 mg/kg 
ALG \IX 19 mg/rot 8/8 100 + lmuron* 2 mg/kg 
* lmuron daily i.p. for 3 weeks after transplantation 
o lmuron doily i.p. for 4 weeks starting 1 week before transplantation 
+Prednisolone doily s.c. for 3 weeks after transplantation 
x ALG weekly s.c. 4 doses starting 1 week before transplantation 
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Transplant function* 
All the figures showing function of the transplant are designed in 
the same way. Urine production/24 hr., blood urea (B.U.), hematocrit 
and urine osmolality are expressed as percentages of values found in 
untreated rats before transplantation. Weight is expressed as percen-
tage of pretreatment value and blood pressure is in mm Hg. Urine pro-
duction and blood pressure were measured once a week; the other 
determinations were carried out twice weekly. Half of the animals 
alive were killed ~t random 50 days after transplantation. In the re-
maining animals, the function studies were continued fortnightly 
until they were sacrificed at I 00 days after transplantation. The 
results obtained after day 50 are not shown in the figures but can be 
found in the Appendix. 
Investigation of toxicity of immunosuppressive agents 
First of all it was investigated whether the various immuno-
suppressive regimens had any direct effect on the parameters used to 
analyse renal function. For this purpose 6 groups of 4 rats each were 
unilaterally nephrectomized and, with the exception of l control 
group, were given immunosuppressive treatment. Parameters of renal 
function in the untreated group were compared to those of the other 
5 groups, each of which received one of the immunosuppressive regi-
mens as used in the transplantation experiments. This is shown in 
figs.S and 6. In all the groups there was a temporary effect of the 
operation on weight and hematocrit reading, while blood pressure 
tended to be at a somewhat higher level than normal. One of the 
batches of ALG (ALG II) was probably slightly toxic as was shown 
by a depression of hematocrit values to 75% of normal during the 
first week after operation (fig.6). Apart from this no appreciable dif-
ferences between treated and untreated animals were noted. 
Isografts 
In fig. 7 a comparison is made between the isografted group and 
the unilaterally nephrectomized group. Neither of the groups re-
ceived immunosuppressive treatment. It is clear that kidney isografts 
were functionally inferior to intact kidneys. All parameters except 
* Although body weight. blood pressure and hematocrit value are not direct parameters of 
renal function, the listed determinations will be referred to as transplant function for 
convenience. 
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Fig.S Effect of immunosuppressive treatment on the parameters used to analyse renal func-
tion. Groups consist of 4 unilaterally nephrectomized rats. Groups receiving Irnuran 
4 mg/kg (broken lines) and Imuran 2 mg/kg +Prednisolone 4 mg/kg (dotted Jines) are 
compared with an untreated control group (solid lines). All parameters. except blood 
pressure are expressed as percentages of values found in untreated rats. The bars in 
the figure indicate the period during which Imuran and Prednisolone were given. 
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Fig. 7 Comparison of function of untreated isografts (broken lines) with untreated uni-
laterally nephrectomized controls (solid lines). The values found in the isografted 
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blood pressure were significantly different. In the isografts, a high 
peak of B.U. was seen during the first week after transplantation and 
the decrease of weight and hematocrit values was more pronounced. 
However, practically normal values were found at 50 days. In con-
trast, urine osmolality, after a sharp initial drop, was only restored to 
a level of 60 - 70% of normal. Accordingly there was an increase in 
urinary output. Nevertheless, isograft function has been considered 
as the best result obtainable with the surgical procedure employed. 
Therefore, the isograft values are included in all the following rJgures 
for comparison with the various allografted groups. 
Allografts 
Fig.8 shows the parameters of function in the untreated alia-
grafted rats. As can be seen, impairment of function was initially the 
same in this group as in the isograft series, but deterioration was pro-
gressive, resulting in death of the animals in 2 weeks. The values of 
the untreated allografted rat, still alive at 50 days, are shown sepa-
rately in flg.9. There were two very high peaks of B.U. during the rrrst 
and second week after transplantation but eventually it settled down 
at about 300%. The bad general condition of this animal was illu-
strated by the severe drop in weight and hematocrit values, which 
tended to rise only slowly after 2l> weeks. At the same time urine 
production rose enormously. Urinary output per day once even ex-
ceeded 60% of the animal's body weight. This rat was exsanguinated 
at day 50 at which time serum osmolality was found to be 
329 m Osm/1 (normal serum osmolality in Wag/Rij rats is 
30 I m Osm/1). This osmolality value would correspond to a urinary 
osmolality of 15% on the graph. However, osmolality of the urine 
was at a constant level of 10%. Thus, the ratio of urine osmolality to 
serum osmolality was much less than I, which might explain the long 
survival of this animal. The reason for the high water uptake is not 
clear. 
The next group (fig. I 0) was treated with Imuran 4 mg/kg. Three 
out of 9 rats were alive at day 50 when two of them were killed, the 
last one died at day 80 from graft rejection. As compared to the iso-
grafts, renal function in this group was severely impaired. Weight and 
hematocrit values were not restored to normal. Hypertension deve-
loped in addition. 
Treatment with a lower dose of 2 mg/kg lmuran resulted in a 
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50-day survival of 6 rats out of 13. Of these, 3 were sacrificed at day 
50. The other 3 showed no change in function and were killed at 100 
days. Renal function was better (fig.!!) than in the previous group as 
demonstrated by significantly lower B.U. and higher urine osmolality 
values. Blood pressure was only little above normal. No deterioration 
occurred after day 50 (see Appendix). 
The values of the group, in which administration oflmuran 2 mg/kg 
was started one week before transplantation (fig.l2) did not differ 
significantly from those of the group receiving Imuran 4 mg/kg. At 
50 days, 4 out or 10 rats were alive, one of which was killed. The 
other 3 died from rejection at 52, 73 and 89 days, respectively. 
When Prednisolone 4 mg/kg was given together with lmuran 
2 mg/kg, the results obtained were better than with Imuran alone. 
Eight out of 10 rats survived for 50 days. Of the 4 animals left alive, 
one died at 55 days from intussusception of the ileum. The values of 
this group, shown in fig.l3, were clearly different from those of the 
isografted group. Improvement over the best of the Imuran treated 
groups (lmuran 2 mg/kg) was demonstrated by higher urine osmolali-
ty values and also by higher weight and hematocrit values. Only 
blood pressure tended to be higher, although the difference was not 
statistically significant. During the 50 - I 00 day period no appreci-
able changes in function were observed. 
It is of interest to note in this group, and in the following groups, 
that discontinuation of treatment at 3 weeks after transplantation 
did not have an adverse effect. 
It was expected that function would clearly improve over the pre-
vious groups with ALG treatment. However, this was only true for 
the treatment with ALG I, the group showing significant improve-
ment over the previous one in all parameters, with the exception of 
hematocrit values. Results after treatment with the other batch 
(ALG II) were not much different from those obtained with lmuran 
and Prednisolone, the only significant difference being lower blood 
pressure. 
In the group, treated with ALGI (fig.l4), all 7 animals were alive 
at day 50. In comparison to the isografted rats, restoration of weight 
and hematocrit values was slower, while B.U. was somewhat higher. 
Blood pressure and 24-hour urine production were not significantly 
different. Urine osmolality was defmitely lower, reaching a final level 
of 50% of normal. Function proved to be stable in 3 rats observed 
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50 
during the 50 - I 00 day period. 
Treatment with ALG II (fig.l5) resulted in 5 out of 7 rats sur-
viving for 50 days. One of the 3 rats observed after day 50 showed 
slowly progressive deterioration of function, resulting in death from 
graft rejection at day 95. Renal function of the other 2 rats did not 
change during that period. Results in this ALG II treated group clear-
ly differed from those in the isografted group in all respects, with the 
exception of blood pressure. 
The difference in effectiveness of the two batches of ALG be-
came even more striking when combined with Imuran. Best recovery 
of function was observed in the animals treated with ALGI together 
with Imuran 4 mg/kg. Of the 5 animals in this group, 4 were alive at 
day 50, when 2 were sacrificed, the other 2 showing no deterioration 
of function during the follow-up until 100 days. Function, as shown 
in fig.l6, was practically similar in this group and in the isografted 
group although minor differences in hematocrit and B.U. level still 
turned out to be statistically significant. In comparison with the 
group receiving ALGI only, concentrating capacity of the kidney 
was clearly improved as demonstrated by a higher urine osmolality 
level. Also weight and hematocrit values were higher. 
In the last two groups, the effect of treatment with ALG II in 
combination with Imuran was studied. In the group treated with 
ALG I! and Imuran 4 mg/kg, 3 out of 5 animals were alive at day 50, 
two of which were observed for 50 days more, when no special fea-
tures were noted. In the last group, treated with ALG II and lmuran 
2 mg/kg all 8 rats survived for 50 days. Renal function did not 
change in the 4 rats observed until day I 00. Results of the tests in 
these last 2 groups are shown in fig.l7 and fig. IS. It is clear that both 
groups were quite unlike the isografted group. When compared with 
the group receiving ALG II only, neither of the 2 groups showed a 
significant difference in any of their parameters. Thus addition of 
Imuran did not improve results in the case of ALG II. 
In the foregoing discussion we have not considered the parame-
ters of function separately but it is clear that, with regard to the con-
dition of the grafted kidney, B.U., urine osmolality and urine pro-
duction/24 hr. are the most relevant. Groups have been reported to 
be different by a certain parameter only if statistically a difference at 
a I% level of significance was found (table IV). If groups were 
different in more than one parameter, this was regarded as further 
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TABLE IV 
STATISTICAL EVALUATION OF GROUP DIFFERENCES 
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support for the conclusions drawn. Of course the question arises 
whether B.U. and urine osmolality were independent parameters of 
renal function. To evaluate a possible interdependence of the two, a 
scatter diagram was made, depicting the relationship between the 
values of blood urea (mg%) and urine osmolality (mOsm/l) obtained 
before sacrificing in the isografted, allografted and unilateral}y 
nephrectomized rats (fig.l9). It is clear that both parameters are re-
lated in a way and indeed, it was not to be expected that severe renal 
damage would selectively affect either the concentrating or the ex-
cretory capacity of the kidney. However, there is a wide range in 
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57 
which considerable changes in urine osmolality were not accompa-
nied by appreciable changes in blood urea, while at osmolality values 
of 600 m Osm/1 or less there is a distinct variation in the severity of 
uraemia. If this is to be compared with the situation in man, one 
should keep in mind that the range of urine osmolality values in the 
rat is twice as great, thus making it a very sensitive index in the latter 
species. From the diagram in fig.20, in which urine osmolality and 
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urine production/24 hr. are plotted in the same fashion, it becomes 
apparent that these two parameters are functionally related. This is 
in agreement with the fact that in the various groups a decrease in 
urine osmolality was generally associated with a higher urinary out-
put. 
Chronic rejection 
It has been discussed before ( cf. fig..4) that in some cases during 
the period of 50 days after transplantation, death from graft rejec-
tion occurred within the first 2 - 3 weeks. However, in some of the 
allografted rats surviving for 50 days, a more chronic pattern of rejec-
tion was observed. Table V shows the incidence of this condition in 
TABLE V 
INCIDENCE OF CHRONIC REJECTION IN LONG SURVIVING ALLOGRAFTED RMS 
no. of rats no. of rats onset of 
surviving showing rejection period 
Treatment groups 50 days chronic rejection (in weeks) 
lmuron 4 mg/kg 3 2 3 
lmuron 2 mg/kg 6 3 
lmuron 2 ms/kg 4 3 3 pretreated 
lmuron 2 mg/kg + 8 4 Prednisolone 4 mg/kg 
ALG 7 0 
ALG II 5 3 
ALG I+ 4 0 lmuron 4 mg/kg 
ALG II+ 
. 3 2 lmuran 4 mg/kg 
ALG II+ 8 2 3-4 lmuran 2 ms/kg 
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the various groups. In each individual case, chronic rejection could be 
recognized with ease from the function data: invariably there was a 
gradual rise in blood urea and 24-hour urine production with a gra-
dual fall in urine osmolality and body weight, while hematocrit 
values remained low. In the majority of cases hypertension deve-
loped. The onset of the rejection period was sometimes marked by a 
temporarily high peak of blood urea, after which the progressive 
changes began. In other cases the onset was less conspicuous. In the 
group, treated with Imuran 2 mg/kg with pretreatment for one week, 
3 out of 4 rats suffered from this condition. Fig.l2, showing func-
tion in this group, reflects clearly the changes as observed in indivi-
dual cases. 
Special mention should be made of two rats in which all the 
changes noted above were observed without a progressive course 
(therefore not included in table V). The frrst rat, which had been 
treated with ALG I, had a rejection crisis during the fifth week after 
transplantation with complete repair within a few weeks (all param-
eters recovering to the same level as found before the rejection epi-
sode). The second rat, from the group treated with ALG II, showed a 
pattern of chronic rejection during weeks 3 and 4 after transplanta-
tion but then recovered, although not completely, during the sub-
sequent weeks. 
Intravenous pyelography 
Intravenous pyelography was performed before sacrificing ani-
mals at 50 or I 00 days after transplantation. In a total of 45 cases, 
successful roentgenograms of transplanted kidneys were obtained 
(10 isografts, 1 untreated allograft and 34 treated allografts). In 39 
of these, defmite hydronephrosis of the grafted kidney was observed, 
in some cases with hydroureter (figs.23, 24 and 25). The 6 kidneys 
having a pelvis of normal size belonged to various treatment groups: 
l isograft, the others allografts, treated with Imuran 2 mg/kg (lx), 
Imuran + Prednisolone (2x), ALGI (lx) and ALG II + Imuran 
2 mg/kg (I x). In order to quantitate the degree of hydronephrosis 
the renal pelvis was measured on the roentgenograms. The greatest 
length in mm was measured and thereafter, along an axis perpendicu-
lar to this, the greatest width in mm. Multiplication of the two 
figures yielded a measure of pelvic size that could be used for the 
purpose of comparison. Mean pelvic size of the isografts amounted to 
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I 04.5 mm2, of the treated allografts to 109 mm2. 
To obtain "normal" values of pelvic size, intravenous pyelogra-
phy was performed in 18 male Wag/Rij rats of the same age as the 
recipients (and isograft donors) used. Unexpectedly 6 of these 18 
rats showed hydronephrosis of the right kidney (the one which was 
used for isogeneic transplantation) as shown in fig.26. Pelvic size of 
these 6 hi'dronephrotic kidneys averaged 86.5 mm2 as compared to 
43.5 mm for the 12 apparently normal right kidneys. More data 
about the incidence of this defect were published recently (Kart, 
1970). It should be mentioned that further investigation of this con-
dition in 2 month old Wag/Rij rats showed 7 out of 20 males to have 
hydronephrosis, occurring only at the right side, while no hydro-
nephrosis was found in 20 females. It has been suggested that this 
lesion is produced by partial obstruction of the right ureter by the 
spermatic artery (Sellers, 1960). Observations at autopsy did not 
confirm the existence of such a mechanism in the Wag/Rij rat: the 
anatomical relationship between the spermatic artery and ureter was 
found to be variable but could not be correlated with the occurrence 
of hydronephrosis. Nonetheless, comparing renal pelvic size in the 
normal and in the isografted kidneys appears to justify the conclu-
sion that severity and incidence of hydronephrosis in the rat are in-
creased after transplantation of the kidney. 
The next question concerned the incidence of hydronephrosis in 
the donor rat used for allogeneic transplantation. Intravenous pyelo-
graphy was performed in 83 BN/Bi males of the same age as the 
donors used in the transplantation experiments (fig.27). Hydro-
nephrosis of the right kidney was seen in 24 cases (29% ). In the 
BN/Bi rat hydronephrosis also occurred on the left side (14 times in 
the 83 rats, 17% ). Moreover, the condition was also found in female 
rats in which the incidence did not differ from that in the males 
(Cohen et al., 1970; Kart, 1970). Thus, incidence of hydronephrosis 
of the right kidney, which was used exclusively in the transplantation 
experiments, was almost as frequent in the allograft as in the iso-
graft donors. Only in a few cases of severe hydronephrosis, seen 
during operation, were the kidneys discarded. Consequently, it can 
be stated that no difference between isografts and allografts with 
respect to the condition of the kidney at the time of transplantation 
has been introduced, so that the comparison of results obtained in 
treated allografted rats with those obtained in isografted rats does 
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not present any difficulties. 
The role of the transplantation procedure itself in the develop-
ment of hydronephrosis was further evaluated by comparing the 
severity of hydronephrosis of kidneys transplanted by 2 different 
persons, A and B. It appeared that in kidneys which had been grafted 
by A (20x, mean pelvic size 137 mm2) there was significantly more 
severe hydronephrosis than in kidneys grafted by B ( l8x, mean 
pelvic size 92 mm2), as determined by measuring the pyelograms 
made on day 50 and 100 (Wilcoxon's test, p < 0.05). No increase in 
severity of hydronephrosis was noted when values obtained at day 50 
were compared to those obtained at day l 00. 
A most important question was now whether the occurrence of 
hydronephrosis had influenced the outcome of the tests used to de-
termine renal function. In other words: could variations in the inci-
dence of hydronephrosis have been responsible for the differences 
observed between the various treatment groups. In fig.7 renal func-
tion of isografted rats with hydronephrosis is compared with that of 
normal rats without hydronephrosis after right-sided nephrectomy. It 
can be seen that, at 50 days after operation, the 2 groups were dif-
ferent only in urine osmolality and 24-hour urine production. Thus, 
it could be, that differences in these parameters were produced by 
hydronephrosis of the kidney. This was checked by making scatter 
diagrams of the relationship between pelvic size on the one hand and 
the last values (obtained before sacrifice in treated allografted rats), 
of urine osmolality and 24-hour urine production on the other 
hand. This is shown in figs.2l and 22. Application of Spearman's 
rank correlation test showed that neither decrease of urine osmolali-
ty values nor increase in 24-hour urine production were significantly 
correlated with increase in pelvic size. Moreover, if treatment groups, 
which were not significantly different in function, were combined, 4 
categories can be distinguished (figs.21 and 22) and it is clear that 
values for pelvic size were evenly distributed in these categories. 
From this, it can be concluded that the observed differences in func-
tion between treatment groups were not attributable to a variation in 
severity of hydronephrosis. 
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Fig.21 Scatter diagram showing the relationship between size of the renal pelvis and urine 
osmolality. Size of the renal pelvis was measured on the roentgenograms and the last 
values of urine osmolality were obtained before sacrifice in treated allografted rats. 
The correlation is not significant (Spearman ranking correlation coefficient - 0.188. 
9S%confidence limits 0.14 7 and -0.522). 
• == poor transplant function (treatment with Imuran alone) 
o = moderate transplant function (treatment with lmuran + Prednisolone, ALG II or 
ALG II +lmuran) 
111 == good transplant function (treatment with ALG I) 
o = excellent transplant function (treatment with ALG I +lmuran) 
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Fig.22 Scatter diagram showing the relationship between size of the renal pelvis and 
24-hour urine production. Size of the renal pelvis was measured on the roentgencr 
grams and the last values of 24-hour urine production were obtained before sacrifice 
in treated allografted rats. The correlation is not significant (Spearman ranking cor-
relation coefficient +0.199. 95%confidence limits 0.548 and -0.149). 
• = poor transplant function (treatment with lmuran alone) 
o = moderate transplant function (treatment with lmuran + Prednisolone, ALG II or 
ALG II + Imuran) 
1111 = good transplant function (treatment with ALGI) 
o = excellent transplant function (treatment with ALGI 1-Imuran) 
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Fig.23 Pyelogram of an untreated isograft at 50 days after trans-
plantation showing moderately severe hydronephrosis 
and hydroureter. 
Fig.24 Pyelogram of an allograft treated with ALG I + lmuran 
4 mg/kg at 100 days after transplantation showing mo-
derately severe hydronephrosis with slightly distended 
appearance of the ureter. 
"' 
"' 
Fig.25 Pyelogram of an untreated allograft at 50 days after 
transplantation showing severe hydronephrosis. Trans-
plant function was severely impaired in this animal. 
Fig.26 Pyelogram of an untreated 8 months old Wag/Rij rat 
showing spontaneous right sided hydronephrosis. The 
left kidney and both ureters are normal. 
Fig.27 Pyelogram of an untreated 
3 months old BN/Bi rat 
showing spontaneous 
hydronephrosis of both 
kidneys. The ureters are 
slightly distended. 
Fig.28 Rat renal allograft. Untreated renal allograft rejected at 11 days after transplantion 
showing some inflltration with lymphoid cells. widespread necrosis of the tubules 
and obliteration of the glomerular capillaries by deposition of eosinophilic material 
and hemorrhage. Some of the tubules contain protein casts. HPS x 140. 
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Fig.29 Rat renal allograft. Untreated renal allograft at 50 days after transplantation 
sho\Ving infiltration with lymphoid cells, obstruction of the glomerular capillaries 
and interstitial fibrosis. Some of the tubules arc dilated, the others have a normal 
appearance. HPS x 140. 
Fig.30 Rat renal isograft. Untreated renal isograft at 100 days after transplantation showing 
focal fibrosis with lymphoid cell inf'lltration. Two other such foci were observed in 
this kidney which looked otherwise normal. HPS x 140. 
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Fig.31 Rat renal allograft Renal allograft treated with Imuran 4 mg/kg. At 50 days after 
transplantation the graft shows heavy infiltration with lymphoid cells, atrophy of 
the tubules and fibrosis. Picture shows a completely obliterated glomerulus. HPS 
X 140. 
Fig.32 Rat renal allograft. Renal allograft treated with Imuran 2 mg/kg with pretreatment 
for one week. At 52 days after transplantation the graft was rejected, showing severe 
arteritis with fibrinoid necrosis of the arterial wall and perivascular fibrosis. The glo-
merular capillaries are obliterated, the basement membranes are thickened. Inf':tltra-
tion with lymphoid cells and tubular atrophy are also apparent. HPS x 140. 
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Fig.33 Rat renal allograft. Renal allograft treated with lmuran and Prednisolone at 50 days 
after transplantation, showing infiltration with lymphoid cells. The glomeruli are aiM 
most completely obliterated. HPS x 140. 
Fig.34 Rat renal allograft. Renal allograft treated with ALGI at 100 days after transplanta-
tion showing slight infiltration with lymphoid cells. Apart from this and some dilata-
tion of the tubules the kidney is normal in appearance. HPS x 140. 
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Fig.35 Rat renal allograft. Renal allograft treated with ALG II and rejected at 95 days after 
transplantation. A section of the ureter shows lymphoid cell inf"lltration in the wall. 
Two arteries show active arteritis and are almost completely obstructed by intimal 
proliferation. HPS x 140. 
Fig.36 Rat renal allograft. Ren::tl allograft treated with ALGI and Imuran 4 mg/kg. At 100 
days no changes were observed. HPS x 140. 
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Fig.37 Rat renal allograft. Same kidney as fig.36. showing normal glomerulus and tubules. 
HPS x 385. 
Fig.38 Rat renal allograft. Renal allograft treated with ALG II and Imuran 2 mg/kg at 50 
days after transplantation showing widespread pyelonephritis: tubules contallling 
polymorphonuclear leucocytes and debris. and focal areas of fibrosis with inf"lltra~ 
tion by inflammatory cells. HPS x 140. 
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Histology 
Biopsy 
Investigation of the material obtained by renal biopsy on day 7 
after transplantation presented some difficulties, which limited the 
value of the information gained. Only a small piece of tissue could be 
taken, thus making appraisal difficult and sometimes impossible. As 
tissue was taken from the cortex, large blood vessels were mostly 
lacking. Moreover, there was considerable variability within the dif-
ferent groups. Because of this only a concise account of the fmdings 
will be given (table VI). 
TABLE VI 
SURVEY OF HISTOLOGICAL FINDINGS IN ALLOGRAFT BIOPSIES 
AT 7 DAYS AFTER TRANSPLANTATION 
cellular obliteration 
Treatment infiltration of glomeruli necrosis 
Untreated ++ ++ +++ 
lmuran, various doses ++ ++ +++ 
lmuron +prednisolone ++ ++ ++ 
ALG ++ + ++ 
ALG II ++ + + 
ALG I+ lmuron 4 mg/kg ++ + + 
ALG II + lmuron 4 and 2 mg/kg ++ + + 
+ = slight 
++ = moderate 
+++=severe 
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In biopsies from the isografts, the only special feature noted in 
some cases was tubular atrophy, supposedly caused by edema. In the 
allografted kidneys, no difference in the severity of infiltration with 
lymphoid cells was noted between treatment groups, all biopsies 
showing a moderately severe cellular infiltrate. In general, deposition 
of moderate amounts of eosinophilic material was observed in the 
glomeruli of allografts that were either untreated or treated with 
Imuran alone, while only small amounts of this material were present 
after treatment with ALGI and ALG II, either alone or in combina-
tion with Imuran. Renal biopsies taken from rats, which subsequent-
ly died before day 50 from rejection of the transplant, often showed 
severe focal tubular necrosis. Wide-spread necrosis of the renal tissue 
was a bad prognostic sign. In 5 rats treated with Imuran and in one 
rat treated with Imuran and Prednisolone showing this, death fol-
lowed within a few days. 
Autopsy 
In general, differences between treatment groups noted at micro-
scopical investigation of the kidney were well correlated with the dif-
ferences found by means of the function tests. 
All kidneys in the unilaterally nephrectomized control groups had 
a normal appearance. The untreated allografts showed the picture of 
complete rejection: heavy infiltration with lymphoid cells, focal 
areas of infarct necrosis, in some cases complete infarction of the 
transplant, necrosis of the tubules, obliteration of the glomerular 
capillaries by PAS-positive material, hemorrhage, and arteritis of the 
large and medium-sized arteries (fig.28). The allograft that continued 
to function without treatment for 50 days, showed severe damage: a 
dense mononuclear infiltrate, partial obstruction of the glomeruli by 
PAs-positive material, extensive interstitial fibrosis and active arteri-
tis (fig.29). In addition, tubular atrophy was present to a variable ex-
tent. 
In order to compare the different treatment groups, microscopi-
cal examination of isografts and treated allografts was performed on 
all the rats which had been alive for 50 days or more after transplan-
tation. 
In the isografted series, some of the kidneys were slightly inm-
trated with lymphoid cells. In two cases pyelonephritis was present 
and in two other cases a few foci of streaky fibrosis associated with 
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lymphoid cell infiltration were noted (fig.30). Glomeruli, tubules 
and blood vessels were normal. 
The 3 groups treated with Imuran alone were quite similar in 
histological appearance, which makes separate discussion unnessary. 
All kidneys were severely damaged (figs.31 and 32). In these groups 
the whole renal tissue was heavily infil.trated with mononuclear cells. 
The glomerular capillaries were obliterated by deposition of eosino-
philic, PAS-positive material and thickening of the basement mem-
branes was prominent. Many of the glomeruli showed necrosis of the 
capillary loops often accompanied by hemorrhage. Although tubular 
atrophy was not equally severe in all cases, all kidneys showed sub-
stantial loss of tubules with marked interstitial fibrosis. In 12 out of 
13 kidneys lesions in the large and medium-sized arteries were ob-
served: active arteritis with fibrinoid necrosis of the vessel wall and 
foci of partly healed arteritis with intimal proliferation and medial 
fibrosis. Arteriolar necrosis was found in 6 cases. Some of the kid-
neys also showed hyperplastic arteriolosclerosis. Pyelonephritis was 
noted once. 
In the group treated with Imuran and Prednisolone, the one rat 
that died at 55 days was distinguishable from the others on its renal his-
tology, glomerular damage and arteritis being more severe. In the 
allografts of this group (fig.33) cellular infiltration appeared to be 
somewhat less dense than in the previous groups. The amount of 
eosinophilic material in the glomeruli was the same as in the allo-
grafts treated with Imuran alone, but necrosis and hemorrhage oc-
curred less frequently. Tubular atrophy also was less severe, while in-
terstitial fibrosis was evident only in 3 out of the 8 cases. In all kid-
neys the large and medium-sized arteries showed evidence of active 
arteritis. In 5 of these rats fibrosis of the arterial wall and intimal 
fibrosis indicated that the process was of longer duration. Arteriolo-
necrosis was observed in two of the kidneys. In all other cases the 
arterioles appeared normal. No pyelonephritis was found in this 
group. 
In the 7 allografts that had been treated with ALGI (fig.34), the 
density of cellular infiltration was about the same as in the previous 
group. However, the condition of the glomeruli and tubules was 
much better, only minor changes being present. No arterial or arte-
riolar changes were noted in any of these kidneys. Interstitial fibrosis 
and pyelonephritis were not observed in this group. 
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After treatment with ALG II, one rat died from rejection of the 
transplant at 95 days after transplantation. In this case the glomeruli 
contained large amounts of eosinophilic material with necrosis and 
hemorrhage. Also, severe arteritis (fig.35), marked interstitial fibrosis 
and pyelonephritis were observed in this kidney. The remaining 4 
kidneys in this group were largely similar to those treated with 
ALG I with the exception of the large and medium-sized arteries. In 
these kidneys evidence of active arteritis, sometimes partly healed, 
was found. The arterioles appeared normal. 
Kidney grafts from the rats, treated with a combination of ALG I 
and Imuran 4 mg/kg were practically similar to the isografts in ap-
pearance (figs.36 and 37), except in one respect: signs of active arte-
ritis were observed in 3 of the 4 cases. Pyelonephritis was not found 
in this group. 
In the last two groups, treated with ALG II and either 2 or 
4 mg/kg of Imuran, cellular infiltration was moderately severe. In 
only 3 out of II kidneys there were notable changes in the glomeruli 
and tubules, the others appeared normal. These 3 kidneys were those 
whose function had been most severely impaired, as demonstrated by 
higher B.U. and lower urine osmolality values. All 3 had evidence of 
arteritis, while arteriolonecrosis was observed in one case and intersti-
tial fibrosis in another. None had pyelonephritis. Of the other 8 kid-
neys, 5 showed active arteritis of the large and medium-sized arteries. 
The arterioles looked normal and no interstitial fibrosis was noted. 
The incidence of pyelonephritis was found to be high, 5 of the 8 rats 
suffered from this condition (fig.38). 
Hypertension (systolic blood pressure over !80 mm Hg on at least 
two occasions) has been observed in 8 allografted rats, treated with 
Imuran (Sx), Imuran + Prednisolone (lx) and ALG H + Imuran 
2 mg/kg (2x). In 7 of these, microscopical investigation revealed ne-
crosis of the arterioles and hyperplastic arteriolosclerosis, changes 
which were observed in 4 other cases from the same groups without 
evidence of preexisting hypertension. 
More or less severe atrophy of the lymphatic tissues of spleen, 
thymus and lymph nodes as well as moderate atrophy of the bone 
marrow was a common fmding in the rats which died from rejection, 
irrespective of their immunosuppressive treatment. These rats were 
all in a uremic state. It was not found in rats-sacrificed at 50 or 100 
days after transplantation. 
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Slight changes in the liver were noted occasionally: slight vacuolar 
degeneration of liver cells in one unilaterally nephrectomized rat, 
treated with ALGI and in one allografted rat treated with ALG II + 
lmuran 2 mg/kg as well as liver cell necrosis in one unilaterally 
nephrectomized rat treated with ALG II and in one allografted rat 
treated with lmuran + Prednisolone. All other tissues examined were 
normal in appearance. 
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DISCUSSION 
The results of the present investigation confirm the advantage of 
using inbred rats in a model system for renal transplantation. Allo-
geneic transplantations across a strong histocompatibility barrier 
were highly reproducable, while isogeneic transplantations were avail-
able as controls. A major disadvantage of the model system was the 
difficulty of the technique, resulting in a high mortality. This has 
also been reported by others (Murray 1969, Sakai et al., 1968). In 
our experiments approximately 50% of the rats surviving the !rrst 24 
hours after transplantation eventually died from causes other than 
graft rejection, the main cause being technical failure. Mortality as a 
result of complications was found to be higher in the isografted than 
in the allografted rats, a fact which was due to the ureteric tissue 
being of a softer consistency in the Wag/Rij as compared to the 
BN/Bi rat. Because of this, successful ureter-bladder anastomoses were 
rather difficult to perform in the isografted group, resulting in a high 
incidence of either leakage or obstruction at this site. On the other 
hand, severe infection causing death of the animal was found almost 
exclusively among the various allografted groups, probably as a result 
of immunosuppressive therapy. 
In the present study, comparing the efficacy of short-term treat-
ment with various immunosuppressive agents, transplantations were 
performed across a strong histocompatibility barrier. The Wag/Rij 
and BN/Bi strain differ at the major H-1 (AgB) locus (Stark and K.Ten 
1969; Stark et a!., 1969) and both skin and kidney grafts between 
the two strains are rejected within 2 weeks. As demonstrated by 
White et a!. (1969), renal allografts transplanted between rat strains 
sharing the same H-1 allele, while differing by several weaker histo-
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compatibility genes, are subject to a much slower rejection process. In 
their experiments renal aiiografts transplanted from Fisher to Lewis 
rats had survival times up to 32 weeks, although skin grafts in the 
same combination were rejected as promptly as H-1 incompatible 
ones (within 12 days). 
In the present experiments serial determinations of body weight, 
hematocrit value, blood urea, urine production per 24 hours, urine 
osmolality and systolic blood pressure together with intravenous 
pyelography before sacrifice, were chosen as the parameters to study 
the grafted rats. "The amount of urinary protein was also measured 
but, in our experience, this was a poor indicator of transplant func-
tion in the rat (data of this determination have not been presented). 
Several other investigators, instead of using survival as the sole cri-
terion, have employed tests to assess function of the transplanted rat 
kidney. In the experiments of White et aL (1969), mentioned above, 
a detailed study was made of transplant function. Body weight, 
blood urea nitrogen (BUN) and serum creatinine levels, 24-hour 
volume, specific gravity and protein concentration of the urine were 
regularly determined. Results of histological examination of biopsy 
and autopsy material was also presented. In these experiments renal 
function was found to be similar in isografted and in unilaterally 
nephrectomized control rats. This is in contrast to our observation of 
a decreased concentrating capacity together with an increased 
urinary output of isografted as compared to normal kidneys. In 
another publication White and Hildemann (1969) reported a slightly 
impaired kidney function in renal isografts with regard to urine 
osmolality values. In this context, it should be pointed out that varia-
bility in urine osmolality values may occur, depending on the nutriti-
onal state of the animal. Bauman et al. (1964) showed that normal 
rats at the end of a 24-hour fasting period concentrated urine to only 
about half the osmolality of urine obtained from rats fed ad libitum. 
In our experiments rats always had free access to food during urine 
collection periods. Thus urine osmolality was measured over a rather 
wide range which made it a very sensitive expression of renal concen-
trating ability. 
Guttmann et al. (1967a,b; 1969b,c; Guttmann and Lindquist, 
1969) measured effective renal plasma flow (ERPF) in anesthetized 
rats on day 7 after transplantation by analyzing the disappearance 
rate of injected 125 I-ortho-iodo hippurate (Blaufox et aL, 1967). 
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They found that rats, living for 7 days on kidneys grafted across a 
strong histocompatibility barrier, were oliguric or anuric with ERPF 
values comparable to those of anephric rats (Guttmann et aL, 
1967b ). The day 7 animal served as a functional and morphological 
control in later experiments of this group. Determination of ERPF is 
an accurate way of measuring renal function in the rat. However, the 
technique is laborious and requires prolonged anesthesia, which 
makes it unsuitable for repeated use over a longer period of time. 
Stuart et a!. (1968b) observed greatly prolonged survival of H-1 
incompatible kidney grafts (73- 142 days) with near normal func-
tion after treatment with donor spleen cells and/or antidonor serum 
prepared in rats of the recipient strain, while rejection episodes could 
easily be recognized by a rise in blood urea nitrogen (BUN), 24-hour 
urine volume and protein concentration together with a fall in urine 
specific gravity. 
The determinations carried out in the present study, in combina-
tion with microscopical investigation, proved very useful to evaluate 
differences between the various treatment schedules. Differences be-
tween groups, with respect to the various parameters, were con-
firmed by statistical testing, using the stringent criterion of signifi-
cance at the I% leveL Changes in body weight clearly reflected the 
general condition of the animals. Hematocrit values were found to 
decrease in all groups during the first 2 weeks after transplantation, 
irrespective of the immunosuppressive treatment given and of the oc-
currence of uremia. Hematocrit values slowly returned to normal 
during subsequent weeks. This may reflect impaired erythropoietin 
production by the grafted kidney. The development of hypertension 
always indicated severe renal damage. Blood urea and urine osmolali-
ty levels were found to be the most useful and reliable parameters of 
transplant function. With respect to urine osmolality values, it was 
found that considerable variation occurred when blood urea was 
within the normal range. 
Intravenous pyelography revealed a high incidence of hydro-
nephrosis in the transplanted kidneys, a fact which has also been re-
ported by others (Feldman and Lee, 1967; Feldman et a!., 1968; 
Guttmann et aL, 1967b; Sakai et a!., 1968, 1969). It is generally 
assumed that the occurrence of hydronephrosis represents failure to 
perform an adequate ureter-bladder anastomosis. In our experiments, 
the importance of the operation technique was clearly demonstrated 
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by the statistically significant difference in severity of hydronephro-
sis, as measured on the pyelograms, between 2 series of kidneys 
transplanted by 2 different persons. However, both the donor and 
the recipient strain showed a tendency to develop hydronephrosis as 
demonstrated by the spontaneous occurrence of this defect in the 
right kidney of approximately one third of the rats in the same age 
groups as those used in the experiments. 
The first 2-3 weeks after transplantation appeared to be of crucial 
importance in the rat model system. Death from graft rejection in 
treated as well as in untreated animals was observed during that 
period, after which time the chance of graft rejection appeared to be 
reduced. When no rejection occurred within 3 weeks, prolonged 
survival for more than 50 days was the rule, in most cases without 
changes in transplant function, even in the absence of immuno-
suppressive treatment. A few cases of similarly prolonged renal allo-
graft survival in the rat have been reported by others: French and 
Batchelor (1969) following administration of antibody against donor 
lymphocytes for 4 days, Guttmann et aL (1969c) following treat-
ment with 10 mg of rabbit anti-rat thymocyte IgG intravenously 
before or shortly after transplantation and Taguchi et aL (1968) fol-
lowing treatment with donor antigen for 4 weeks. With regard to the 
existence of a critical period after renal transplantation, the situation 
resembles that found in man. According to Moore and Hume (1969) 
the major period of hazard in man is during the early months after 
transplantation when kidneys from related living donors are used. 
For cadaver donor transplants this period is considerably longer (l-2 
years). Furthermore it appears that the pattern of transplant 
function for kidneys from cadaver donors as well as from related 
living donors during the first month after transplantation, is of parti-
cular importance in determining the ultimate success or failure of the 
graft. 
Treatment for 3 weeks after transplantation did not prevent re-
jection in all rats. In a proportion of the cases (especially in those 
treated with Imuran as the sole immunosuppressive agent) a pattern 
of slowly progressive rejection was observed starting about 3 weeks 
after transplantation and resembling that found in larger animals and 
in man. Microscopical investigation in these cases, either after spon-
taneous death or after sacrifice, confirmed that active rejection was 
taking place in the graft. In 2 other cases a rejection crisis was fol-
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lowed by spontaneous recovery. 
Differences between groups with respect to transplant function 
were well correlated with those observed at microscopical examina-
tion while differences in 50-day survival per group were largely in 
agreement. However, it should be realized that the histological dif-
ferences observed between the groups may not have been entirely 
due to the immunosuppressive regimens, since treatment had been 
discontinued for at least 4 weeks by the time of investigation. 
The fact that concentrating ability in the isografted rats remained 
below that found in untreated unilaterally nephrectomized control 
rats was probably the result of incomplete recovery from the ischae-
mic injury at the time of transplantation. The occurrence of hydro-
nephrosis in the isografts might have been a contributing factor but 
could not fully explain it, since it was found that in the allografts, 
increase in size of the renal pelvis was not correlated with a decrease 
in renal concentrating capacity. 
Although rejection time of untreated allografts was fairly con-
stant (mean survival time 11.3 days) one rat managed to survive 50 
days after transplantation. Hyposthenuria and massive polyuria de-
veloped in this animal. It is not clear whether this diabetes insipidus 
was caused by the immune reaction, affecting the distal tubules in 
particular, by the severe degree of hydronephrosis present, or by 
other causes. When this rat was sacrificed, at 50 days after transplan-
tation, severe histological damage of the kidney with wide-spread in-
terstitial fibrosis was observed. Exceptional cases of long survival in 
untreated allografted rats have also been reported by Stuart et a!. 
(1968b) and by Tinbergen (1968)_ 
Detailed morphological studies of the rejection process in un-
modified rat kidney grafts have been performed by Guttmann eta! . 
. (1967b), by Feldman and Lee (1967) and by de Vries eta!. (1968). 
In our experiments, untreated allografts were always completely 
destroyed by the time the animal died. 
Immunosuppressive treatment with lmuran alone was not particu-
larly effective. Day 7 biopsies of Imuran treated allografts were simi-
lar to those from untreated allografts with respect to the severity of 
tubular necrosis and obstruction of the glomeruli. It is of interest 
that treatment with the lowest dose (2 mg/kg) resulted in better 
transplant function, higher 50-day survival percentage and lower inci-
dence of chronic rejection than treatment with the higher doses, 
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although the histological picture was similar in both groups. When 
chronic rejection occurred, the process was already evident during 
the third week after transplantation, prior to the cessation of treat-
ment. Reports about Imuran treatment in the rat are contradictory: 
with intraperitoneal doses of 8 and 4 mg/kg, Tinbergen (1968) ob-
tained 50-day survival figures of 60% and 45% respectively, while 
intraperitoneal doses of 6 mg/kg in the experiments of French and 
Batchelor (1969) were ineffective (mean survival time 8.5 days). It 
has b~en shown in dogs, that lmuran therapy is most effective when 
started 7 to 30 days before transplantation (Starzl 1964, p.l33). In 
our experience with the rat, pretreatment with Imuran for one week 
before transplantation (in addition to posttransplant treatment) did 
not improve function of the graft. On the contrary, after this pre-
treatment mortality from postoperative hemorrhage was twice as 
high as in the other groups. 
Treatment with a combination of Imuran and Prednisolone, 
which is the standard therapy in clinical practice, was clearly more 
effective than Imuran alone as demonstrated by better transplant 
function and less histological damage in the former group. 
It is of interest that the two batches of ALG (I and II) produced 
and administered in the same fashion, were not equally effective. The 
lymphocytotoxic titer and the ability to prolong skin graft survival 
were higher for ALG I as compared to ALG IL ALG I also proved 
more effective in suppressing the immune reaction after renal trans-
plantation. Our data on transplant function and histology clearly 
show that, while treatment with a potent batch of ALG may be 
superior to the usual therapy with Imuran and corticosteroids, treat-
ment with a less potent batch may not be so. This once more illustra-
tes the need of a reliable method to assess the immunosuppressive 
potency of a given ALG preparation, especially when it is to be used 
in human transplantation. At present anti-human lymphocyte sera 
must be tested in vivo using sub-human primates (Balner, 1969). 
Guttmann et al. ( 1967 a) treated rats prior to renal allotransplan-
tation intravenously with heterologous rabbit anti-rat thymocyte 
serum (ATS 0.7 and 4.0 ml/rat), its IgG fraction (6 and 10 mg/rat) as 
well as its pepsin digested fragments (23 and 30 mg/rat) and obtained 
effective renal plasma flow (ERPF) values within the normal range at 
day 7. A severe immune complex nephritis developed after treatment 
with the crude unadsorbed material. The IgG preparation contained 
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antibody to glomerular basement membrane antigens but its nephro-
toxicity could be reduced by subcutaneous instead of intravenous ad-
ministration (Guttmann et al., 1967a; Lindquist et al., 1969). A total 
of 1 0 mg of ALG, administered intravenously around the time of 
transplantation was also found to be effective in prolonging graft sur-
vival with normal renal function and histology, while subcutaneous 
administration of 10 mg ALG (in 2 rats) was hardly effective 
(Guttmann et al., 1969c). The data of the present investigation failed 
to support the suggestion given by the above-cited experiments that 
subcutaneous administration is hardly effective. However, the total 
dosage of 4 weekly injections of 19 mg of IgG, as given in our study, 
was higher than in the experiments discussed above (and, incidental-
ly, much higher than the doses given to human renal transplant reci-
pients). On the other hand, from our observations with light micro-
scopy, there was no evidence of nephrotoxicity from either of the 2 
ALG batches. 
Although day 7 biopsies from ALG treated allografts showed 
much less tubular necrosis and obliteration of the glomeruli than 
biopsies from Imuran treated allografts, all showed the same amount 
of lymphoid infiltration, suggesting that not all of the cells present 
were engaged in an actual immunological attack against the graft. 
Our interest in treatment with a combination of ALG and Imuran 
was based on earlier work (de Vries et al., 1968) in which continued 
treatment with Imuran was seen to be very efficient in suppressing 
the vascular component of graft rejection, while not preventing the 
glomerular damage. In these studies crude, unpurified ALS, also ad-
ministered over longer periods of time, was found to be very ef-
fective in preventing the glomerular damage, while incompletely pre-
venting the vascular lesions. It has been postulated that the necro-
tizing arteritis is caused by an antibody-mediated rejection process, 
while the glomerular damage is mainly due to cell-mediated rejection. 
It has been shown by Israel and de Vries (1970) that ALS suppresses 
both antibody-mediated and cell-mediated immunological processes, 
while Imuran, under the conditions of their experiments, only sup-
presses antibody-mediated immunological processes. In view of these 
results the fmding that Imuran does not prevent glomerular damage 
can be explained. It should be stressed, however, that the present ex-
periments differ from those discussed above in that treatment was 
discontinued after 3 weeks. In the present experiments results of 
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treatment with the potent batch ALG I were indeed improved by ad-
dition of Imuran. For the less potent batch ALG II no such effect on 
function and histological changes of lmuran addition was observed, 
though this might have been due to the high incidence of pyelone-
phritis in this group, not only as a fmding at autopsy, but also as a 
complication leading to early death. Allografts, treated with ALGI 
and Imuran 4 mg/kg were practically similar to isografts in function 
as well as histology. It was quite remarkable that, although transplant 
function in this group did not reveal signs of chronic rejection, histo-
logical evidence of a discrete but active arteritis was observed, a 
feature which was totally absent from the allografts treated with 
ALGI alone. It is possible that ALG and Imuran have synergistic ac-
tions, which could explain the improved results after combined treat-
ment but not the discrepancy in histological findings. Another pos-
sibility is that antibody formation, in particular against ALG protein, 
was suppressed by simultaneous administration of Imuran thus 
avoiding a rapid immune elimination and thereby a reduced efficacy 
of ALG. The early arteritis seen at 50 and 100 days after transplanta-
tion would then be the result of humoral antibody formation against 
the graft following cessation of Imuran treatment at 3 weeks after 
transplantation. Suppression of antibody formation to ALG might 
also have the advantage of preventing the immunological complica-
tions of ALG treatment, since it has been shown that the partial sup-
pression of humoral antibody formation by ALG may lead to serum 
sickness (Cohen et aL, 1970). 
Jeejeebhoy et aL (1968) found that the ability of antilymphocyte 
plasma to prolong skin allograft survival in mice was improved when 
given in conjunction with 6-mercaptopurine. On the other hand, 
Starzl et aL (1967) observed only a slight potentiation of the effect 
of ALG with respect to renal allograft survival in dogs by the sim ulta-
neous use of Imuran, although the degree of histological injury 
seemed to be reduced. In the treatment of human renal allograft re-
cipients, ALG has been given as an adjunct to the conventional im-
munosuppressive drugs, not because combined therapy was expected 
to be more effective but because of a reluctancy to replace the usual 
therapy altogether in favor of ALG alone for which clinical experien-
ce was lacking and particularly when no reliable means to diagnose 
rejection at an early stage were available. Pioneer work in clinical use 
of ALG has been done by Starzl and his coworkers (Starzl et aL, 
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1967, 1969) who have at present the largest series of patients, 
treated with horse anti-human lymphocyte globulin. During the early 
postoperative months, recipients of kidneys from related living 
donors received amounts of 14 to 50 mg/kg per week by intramuscu-
lar injection. As compared with previous groups a reduction in mor-
tality was achieved by ALG therapy while lower doses of Imuran and 
Prednisone than before were required to maintain the same level of 
renal function. After discontinuing ALG, renal function did not 
deteriorate. The experience with ALG in cadaver renal transplanta-
tion was still insufficient to justify conclusions. 
In human renal transplant recipients, sporadic attempts to discon-
tinue immunosuppressive treatment entirely have generally been fol-
lowed by irreversible deterioration of transplant function. In our ex-
periments, cessation of treatment in rats with stable transplant func-
tion did not have any adverse effect. However, histological signs of 
active rejection were found in a proportion of these rats. The vascu-
lar lesions observed at 50 and 100 days after transplantation in some 
of the rats with excellent renal function after combined treatment 
with ALGI and lmuran, were essentially the same as those observed 
in biopsies from long functioning human renal transplants. Our re-
sults in the rat suggest that treatment with high doses of potent ALG 
during the early period after transplantation is highly effective and 
that ALG therapy can be discontinued without deterioration of 
transplant function. However, the low grade rejection process oc-
curring at a later stage indicates that complete omission of Imuran 
therapy is unwarranted. Possibly, adaptation of the graft to the cell-
mediated component of graft rejection, initially suppressed by ALG, 
is easier obtained than adaptation to the antibody-mediated compo-
nent. 
In human renal transplantation, the well known morbidity asso-
ciated with clinical ALG therapy as reported by Kashiwagi et a!. 
(1968) and the fact that, after a 2-3 weeks course of ALG, apprecia-
ble amounts of circulating antibody against ALG protein can be de-
tected (Iwasaki, 1967) suggest that short term treatment with high 
doses of ALG might be more efficient than prolonged courses with 
this material. As long as infections and sepsis are the major cause of 
death in human renal transplantation, the fact that doses of other 
immunosuppressive drugs can be reduced when given as an adjunct to 
ALG is of great advantage (Starzl eta!., 1967, 1969). Besides the risk 
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· of prolonged treatment with high doses of immunosuppressive agents 
promoting the development of malignant tumors (Bainer, 1970) 
might be reduced. Though cessation of immunosuppressive therapy is 
possible in the rat, it is not clear whether this may be extrapolated to 
man. More research in this direction appears indicated. 
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SUMMARY 
In the introduction, some subjects which are relevant to the ex-
periments are briefly discussed. Skin grafting experiments, having 
contributed largely to our knowledge of transplantation biology, are, 
for several reasons, inadequate for studying the effect of immuno-
suppressive treatment on renal transplants. Results of experimental 
renal transplantation in larger animals such as dogs have until recent-
ly been difficult to evaluate, mainly because of the variation in histo-
compatibility difference between randomly selected members of the 
same species. Transplantations between highly inbred strains of ani-
mals are not subject to this variation. 
In the experiments, a microvascular technique modified after 
Fisher and Lee, was used for orthotopic transplantation of the rat 
kidney. Untreated allogeneic transplants between two highly inbred 
strains, BN/Bi and Wag/Rij, have an almost constant rejection time. 
Isogeneic transplantations between rats of the Wag/Rij strain were 
performed as controls. Both host kidneys were removed during oper-
ation. On day 7 an open wedge biopsy was taken from the trans-
plant. Immunosuppressive treatment with various regimens of Imu-
ran, Prednisolone, and ALG (rabbit anti-rat thymocyte globulin) was 
given to groups of allografted rats for a limited period of 3 weeks 
after transplantation. The groups were compared with respect to 
50-day survival, renal function and histology of the transplant. Half 
of the survivors were sacrificed at 50 days after transplantation, the 
remainder after 100 days. Serial determinations of body weight, 
hematocrit value, blood urea, urine osmolality, 24-hour urine pro-
duction and systolic blood pressure were chosen to assess function of 
the transplant. In addition, intravenous pyelography was performed 
before sacrificing the animals. 
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After excluding those animals which died as a result of a technical 
failure, a total of 95 transplants remained. Survival percentage at 50 
days after transplantation was 100% in the untreated isografted 
group. Survival percentage was lower in 3 allografted groups treated 
with Imuran alone than in the various groups treated with Imuran + 
Prednisolone or with ALG. Death from graft rejection was not ob-
served between 22 and 50 days after transplantation when the 
immunosuppressive therapy was discontinued. 
In the isografted group blood urea rose to 450% of normal, re-
turning to normal values after one week. Urine osmolality fell to 30% 
of normal with recovery to a level of 65% after 4 weeks. After an 
initial decrease, weight and hematocrit values returned to normal in 6 
weeks. In the untreated allografted group deterioration of function 
was progressive, resulting in 80% mortality within 2 weeks. After 
treatment for 3 weeks with Imuran values for blood urea and urine 
production stabilized at high levels while urine osmolality was very 
low. Weight loss and decreased hematocrit values were not complete-
ly restored. A high incidence of chronic rejection was observed in 2 
of the lmuran treated groups. Results were improved when Predni-
solone was given together with Imuran. When this regimen or ALG, 
either alone or in combination with Imuran, was used it was noted 
that cessation of the treatment at 3 weeks after transplantation was 
not followed by deterioration of transplant function. Two different 
batches of ALG (I and II) were given. Results of treatment with 
ALG II were similar to those of treatment with Imuran + Predni-
solone. When ALG II was given together with Imuran, results were 
not appreciably better. However, transplant function was clearly im-
proved by treatment with ALGI as compared to the previous groups. 
Treatment with ALGI in conjunction with Imuran resulted in trans-
plant function which was similar to that of isografts. 
Intravenous pyelography revealed hydronephrosis in 39 out of 45 
cases, a condition which was also found to occur in a proportion of 
the normal donor and recipient animals. 
Histologically, obliteration of the glomeruli and tubular necrosis 
was most severe in biopsies taken from allografts treated with lmuran 
alone. 
At autopsy, the untreated allografts were completely destroyed. 
Advanced destruction of glomeruli and interstitial fibrosis were ob-
served in all Imuran treated allografts. Changes were slightly less 
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severe in the allografts treated with lmuran + Prednisolone. Only 
minor changes were present in allografts treated with ALG I. In ap-
pearance. allografts treated with ALG I + Imuran were practically 
the same as isografts, except for the presence of active arteritis in the 
majority of the animals. Arteritis of the large and medium-sized arte-
ries was the main lesion in the allografts treated with. ALG II either 
alone or in combination with Imuran. 
In the discussion it is concluded that: 
The rat model system is highly suitable for screening of different 
regimens of immunosuppressive treatment in renal transplanta-
tion. 
The efficacy of immunosuppressive regimens can be evaluated in 
this model system by performing some rather simple function 
tests. Of these, blood urea and urine osmolality are particularly 
valuable to quantitate transplant function while results correlate 
well with the histological fmdings. 
A potent ALG is needed to improve the results of treatment with 
lmuran + Prednisolone. 
Results, similar to those obtained in isografts, can be obtained by 
treatment with a potent ALGin conjunction with Imuran. 
The cessation of immunosuppressive therapy at 3 weeks after 
transplantation in this model system is not followed by a deterio-
ration of transplant function during a period of at least I 00 days 
after transplantation. Nevertheless, arteritis occurred in the 
majority of animals after cessation of treatment, which was not 
reflected in the function tests. An exception to this was the group 
treated with ALG I, which remained free from arteritis. 
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SAMENVATTING 
In de inleiding worden enkele onderwerpen met betrekking tot de 
experimenten kort besproken. Huidtransplantatie experimenten, die 
onze kennis van de transplantatiebiologie belangrijk hebben verrijkt, 
zijn om verschillende redenen ongeschikt om het effect van immuno-
suppressieve behandeling op niertransplantaten te bestuderen. Resul-
taten van experimentele niertransplantatie bij grotere dieren, zoals hon-
den, waren tot voor kort moeilijk te interpreteren, voornamelijk door 
de variatie in histocompatibiliteitsverschil tussen willekeurig gekozen 
!eden van dezelfde soort. Transplantaties tussen sterk ingeteelde dier-
stammen zijn niet aan deze variatie onderhevig. 
In de experimenten werd gebruik gemaakt van een gewijzigde 
microvasculaire techniek volgens Fisher en Lee voor orthotope trans-
plantatie van de rattenier. bnbehandelde allotransplantaten tussen 
twee sterk ingeteelde rattestammen, BN/Bi en Wag/Rij, hebben een 
vrijwel constante afstotingstijd. Als controles werden isotransplanta-
ties tussen ratten van de Wag/Rij stam verricht. Beide nieren van de 
ontvanger werden tijdens opera tie verwijderd. Op de 7e dag werd een 
open wigbiopsie uit het transplantaat genomen. Immunosuppressieve 
behandeling met verschillende schema's van Imuran, Prednisolon en 
ALG (konijn anti-rat thymocyten globuline) werd gedurende een be-
perkte periode van 3 weken na transplantatie aan groepen allogeen 
getransplanteerde ratten toegediend. De groepen werden vergeleken 
wat betreft 50-dagen overleving, nierfunctie en histologie van het 
transplantaat. De helft van de overlevenden werd 50 dagen na trans-
plantatie opgeofferd, de rest na 100 dagen. Herhaalde bepalingen van 
lichaamsgewicht, hematocriet, ureumgehalte van het bloed, osmolali-
teit van de urine, 24-uurs urineproductie en systolische bloeddruk 
werden gekozen om de functie van het transplantaat te testen. 
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Tevens werd, alvorens de dieren op te offeren, intraveneuze pyelogra-
fie verricht. 
Na uitsluiting van de door technische fouten omgekomen dieren, 
bleef een totaal van 95 transplantaten over. Vijftig dagen na trans-
plantatie was het overlevingspercentage I 00% in de onbehandelde 
isogeen getransplanteerde groep. In 3 allogeen getransplanteerde 
groepen, behandeld met aileen Imuran, was het overlevingspercentage 
lager dan in de verschillende groepen behandeld met lmuran + Pred-
nisolon of met ALG. Sterfte ten gevolge van afstoting van het trans-
plantaat werd niet gezien van de 22e tot de 50e dag na transplantatie, 
toen de immunosuppressieve behandeling was gestaakt. 
In de isogeen getransplanteerde groep steeg het ureum tot 450% 
van normaal met terugkeer tot de norm na 4 weken. De osmolaliteit 
van de urine daalde tot 30% van normaal met herstel tot een niveau 
van 65% na 4 weken. N a een aanvankelijke daling, herstelden li-
chaamsgewicht en hematocriet zich in 6 weken. In de onbehandelde 
allogeen getransplanteerde groep ging de functie in toenemende mate 
achteruit, met 80% sterfte binnen 2 weken als gevolg. Na behandeling 
met Imuran gedurende 3 weken bleven de waarden voor ureum en 
urineproductie hoog, die voor osmolaliteit van de urine zeer Jaag. Wat 
betreft het gewichtsverlies en de hematocrietdaling, trad geen volle-
dig herstel op. Chronische afstoting werd frequent gezien in 2 van de 
met Imuran behandelde groepen. Betere resultaten werden bereikt 
door Prednisolon sam en met Imuran te geven. Met dit schema, alsook 
met ALG, hetzij aileen hetzij in combinatie met Imuran, bleek het 
staken van de behandeling 3 weken na transplantatie niet te worden 
gevolgd door achteruitgaan van de functie van het transplantaat. 
Twee verschillende partijen ALG (I en II) werden gegeven. Met 
ALG II werden gelijke resultaten bereikt als met Imuran + Predniso-
lon. Wanneer ALG II sam en met Imuran werd gegeven, waren de re-
sultaten niet noemenswaardig beter. De functie van het transplantaat 
verbeterde echter duidelijk ten opzichte van de vorige groepen door 
behandeling met ALG I. Behandeling met ALG I en Imuran samen 
had een zelfde functie als van isotransplantaten ten gevolge. 
Bij intraveneuze pyelografie werd hydronefrose gevonden in 39 
van de 45 gevallen, een toestand die eveneens werd aangetroffen bij 
een gedeelte van de normale donor en ontvanger dieren. 
Histologisch was obliteratie van de glomeruli en tubulusnecrose 
het emstigst in biopsieen van allotransplantaten, behandeld met 
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Imuran aileen. 
Bij sectie bleken de onbehandelde allotransplantaten volledig 
vernietigd te zijn. V er voortgeschreden destructie van glomeruli en 
interstitiele fibrose werd gezien in aile met Imuran behandelde allo-
transplantaten. Wat minder ernstig waren de veranderingen na behan-
deling met Imuran + Prednisolon. Met ALG I behandelde allotrans-
plantaten hadden slechts geringe veranderingen. Allotransplantaten, 
behandeld met ALG I + Imuran, waren microscopisch vrijwel gelijk 
aan isotransplant<!ten met uitzondering van de actieve arteritis die bij 
het merendeel voorkwam. Arteritis van de grate en middelgrote arte-
rien was de voornaamste laesie in de allotransplantaten die met 
ALG II, hetzij aileen hetzij gecom bineerd met Imuran, waren behan-
deld. 
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In de discussie wordt het volgende geconcludeerd: 
Het modelsysteem bij de rat is zeer geschikt voor vergelijkend on-
derzoek van verschillende immunosuppressieve behandelingssche-
ma's bij niertransplantatie. 
De werkzaamheid van immunosuppressieve schema's kan in dit 
modelsysteem met behulp van enkele vrij eenvoudige functiebepa-
lingen worden beoordeeld. Hierbij zijn het ureumgehalte van het 
bloed en de osmolaliteit van de urine bijzonder waardevol bij de 
kwantificering van de functie van het transplantaat, terwijl de re-
sultaten goed correleren met de histologische bevindingen. 
Een sterk werkzaam ALG is nodig om de resultaten van behande-
ling met Imuran + Prednisolon te verbeteren. 
Door behandeling met een sterk werkzaam ALG gecombineerd 
met Imuran kunnen resultaten worden verkregen die gelijk zijn 
aan die bij isotransplantaties. 
Het staken van de immunosuppressieve behandeling 3 weken na 
transplantatie heeft in dit modelsysteem geen verslechtering van 
de functie van het transplantaat ten gevolge gedurende tenminste 
I 00 dagen na transplantatie. Niettemin kwam bij het merendeel 
van de dieren arteritis voor na het staken van de behandeling, het-
geen niet werd weergegeven door de functiebepalingen. Een uit-
zondering hierop was de met ALGI behandelde groep, die vrij 
bleef van arteritis. 
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APPENDIX 
-~ TABlE A 
WEIGHT, AVERAGE VALUES WITH STANDARD DEVIATIONS AND NUMBERS IN DIFFERENT TREATMENT GROUPS; AVERAGES ARE EXPRESSED AS PERCENTAGES OF 
WEIGHT AT ONE WEEK BEFORE TRANSPLANTATION 
eontroh, vnllolerol nephrectomy 
untreoted lm 4ms/kg lm 2/Pred 4 ALGI 
' ' 
100.0 
o.o 4 99.2 
0 .5 4 94 .5 
' 
o.o 4 100.0 
0.9 4 100.5 
0.5 4 95.0 
3.3 4 91.5 
4.8 4 91.2 
0 
' 
o.o 4 100.0 0.0 
.2 4 100.0 1.1 
.8 4 95.0 3.7 
2.3 4 90.7 9.8 
1.5 4 86.2 12.2 
isografls allogrofts 
ALG II ALG f/lm 4 untreated untreated 
' ' ' ' 
0.0 100.0 o.ooo 7 o.o 10 
0.9 -4 99.8 0.766 10 1.1 10 
I . 2 93.6 4.91710 3 .6 10 
0. 8 66.3 5.207 10 3' 7 10 
0.' 82.8 5.07210 3. 3 9 
2 100.0 
3 95.5 
97 .o 
5 93.5 
6 95.5 
0.8 4 93.0 
0.5 4 86.7 
0.5 4 93.0 3 .5 4 93 0.9 4 90.7 10.5 
100.0 
99.5 
92.5 
92.5 
93.5 
94 .o 
95.0 
95 .0 
95 .7 
96.2 
94' 2 
95.0 
66.5 
91 .7 
o.o 
0.5 
3.1 
6. 2 
4.5 
4.2 
3. I 
3. I 
2. 0 
2. 2 
0.9 
100.0 
99.2 
97.2 
95 .0 
92.0 
93 .7 
90.7 
94' 7 
I .S 65.9 4.35710 
100.0 
100.0 
90.1 
86.2 
78.5 
75 .6 1 .5 3 6 
91.2 
8 94.2 
9 91 .o 
10 91.7 
11 91.0 
12 94.2 
13 92.0 
14 93.2 
15 91.2 
16 94.0 
17 91.7 
18 93.5 
19 96.5 
20 95.5 
0.5 4 94.0 
0.9 4 
1.4 4 94.7 
0.9 
2.1 4 97.2 
0.9 
0.8 4 97.7 
l.S 
I .2 ( 101 .5 
0.8 
2.6 4 100.0 
0.7 2 107.0 
0.7 2 110.0 
0.7 2 112.0 
2.9 4 93.7 
92.5 
1 .s 4 n.o 
94.0 
2.7 4 91.2 
96.2 
2.2 4 96.5 
.2 -4 67.0 10.6 
.2 -4 96.0 0.0 
.8 -4 93.0 6.7 
. 4 
.3 -4 93.0 87 
.7 
.0 -4 96.7 5.1 
1.7 4 96.5 1.2 4 95.7 3.2 
95 .5 9. 1 
2.6 2 94.0 1.4 2 102.0 o.o 
2.6 2 100.5 0.7 2 91.0 16.9 
1.4 2 99.5 0.7 2 66.5 26.9 
l.-4 2 !05.0 o.o 2 67.5 33.2 
2. I 
7 
2. 2 
92.0 1.6 
95.2 2.5 
93.7 3.2 
102.0 1.4 
103.0 o.o 
102.0 J.-4 
96.0 
97.5 
96.7 
99' 2 
98.5 
103' 0 
104.5 
105.5 
1.7 
0. 9 
0. 8 
0,5 
I. 2 
0. 9 
0.7 
0.0 
0.7 
0.7 
65.4 -4.9-4810 
68.2 5.45210 
87.1 4.66310 
90.0 5.53710 
66.9 5.404 10 
92.1 4.954 10 
91.8 4.848 10 
93.3 5.14310 
92.2 
94.8 
93.2 
96.8 
99.0 
98.8 
5.356 9 
3.457 10 
4.066 
6. 220 5 
7. 776 5 
7.049 
10 
II 
12 
13 
14 
IS 
16 
17 
18 
19 
20 
-0 
"' 
lrn 4rng/kg 
• 
100.0 
99.5 
92 .2 
4 82.8 
5 77.3 
6 70.0 
70,3 
8 74.3 
9 74.3 
10 77.3 
II 79.6 
12 81 .6 
13 79.6 
14 79.6 
15 78.3 
16 78.0 
17 74.0 
18 71 .0 
19 71 .o 
20 
• 
o.o 6 100.0 
I .5 9 99.6 
4.8 9 90.0 
8.7 8 83 
10.2 8 75 .o 
13.4 6 73.8 
5.6 3 71.5 
7.2 3 73.1 
8.9 3 76.0 
8. I 3 77.1 
8.5 3 74 
7,6 3 78.8 
6.1 3 76.8 
4.1 3 80.5 
5.6 3 79.8 
1 .0 3 81 .8 
o.o 
0.0 I 90.3 
0.0 I 90.6 
93.0 
lm 2 lrn 2 pretreated lrn 2/Pred 4 
' 
0.0 9 100.0 
2. 8 
3.3 
5.3 
•. 9 
3. 8 
6.9 
2. 2 
... 
.., 
a. a 
.., 
9.0 
5. 5 
9.4 
7. 6 
.., 
1.1 
5. 2 
13 99.5 
13 92.6 
12 83.5 
10 77.0 
79.4 
77.4 
6 78.7 
6 78.0 
6 78.2 
6 74 0 
6 ,75 
6 75.0 
6 76' 5 
6 74.0 
75.7 
68.6 
73.5 
67 .o 
• 
0.0 10 100.0 
.7 
5 .• 
3 .I 
5.1 
5 .• 
7. 9 
3. 8 
5 .• 
5.3 
8. 8 
6.6 
7.5 
8. 2 
10.8 
9 .• 
8. 9 
10.6 
0.0 
10 100' 1 
10 87.5 
10 82 .9 
10 77.7 
74. I 
5 77.7 
76.0 
79.5 
78 
82 .7 
84 
85 8 
83 
86.0 
87.5 
90.0 
95.6 
95 .6 
98.3 
o.o 
1.1 
3.5 
3.7 
6.2 
8.0 
5.2 
5. 8 
2. 8 
6.1 
4. 3 
5.5 
•. 9 
7 .• 
3. 4 
6.5 
2.6 
3 .5 
3 .5 
3.5 
allografts 
' 
100.0 
10 99' 1 
10 95' 8 
10 85.5 
9 81 '7 
8 83.0 
8 79. I 
8 84.8 
8 84.0 
8 86' 8 
8 84.8 
8 89. 
8 88. I 
90 
91.8 
93.2 
93.2 
94.0 
98.6 
99' 0 
ALGI 
' 
o.o 6 100.0 
1.4 7 99.4 
3.4 7 91.4 
2.2 7 84.0 
3.8 7 81.7 
5.5 7 82.6 
5.2 7 84.0 
7.2 7 83.2 
7.7 7 84.8 
9.0 7 84.4 
8.6 7 85.0 
9.5 7 85.8 
7.8 7 86.2 
8.1 7 85.4 
8.1 7 85.2 
7.9 7 84.4 
9.0 5 83.2 
13.1 3 88.3 
14.7 3 88.6 
16.3 3 83.6 
ALG II ALG 1/lrn 4 ALG 11/lrn 4 
' • 
0.0 100.0 
1.1 7 100.6 
6.3 7 93.6 
5.8 7 88.0 
7.2 7 82.6 
6.1 5 84.5 
4.1 5 86.0 
7.2 5 85.2 
3.7 5 91.0 
7.3 5 91.7 
6.5 5 94.0 
6.3 5 92.7 
7.2 5 96.2 
8.2 5 95.0 
9.2 5 96.7 
9.7 5 96.0 
12.0 4 92.6 
17.0 3 100.5 
19.0 3 103.5 
23.4 3 108.0 
o.o 5 \00.0 
2.0 
... 
5.7 
8.3 
5.0 
7.7 
7.7 
9. 3 
10.2 
9. 2 
9.9 
9.6 
9. 2 
10.2 
8.7 
9.0 
12' 0 
10.6 
9.8 
5 100.5 
s 91.6 
s 87.8 
5 79.7 
81.0 
4 80.0 
4 83.6 
85.0 
89.0 
88.3 
4 91 .3 
90.6 
92.6 
90.3 
93.6 
96.5 
101.5 
104' 0 
106.5 
0.0 
2.5 
8.3 
5.1 
8.2 
8.5 
10.3 
8.3 
7.5 
7. 2 
6 .• 
8.0 
8.3 
10.2 
10.6 
9 
.I 
2.1 
7 .o 
6.3 
ALG 11/lrn 2 
' 
100.0 
4 99.7 
5 90.1 
5 85.7 
85.8 
84.5 
82' 1 
80.3 
so. 2 
81.2 
82 .6 
82.8 
82 '7. 
84,7 
3 83 '8 
3 85 .o 
89' 7 
95.2 
91.7 
2 94.7 
0.0 
1.0 
3.5 
.., 
,.. 
3. 8 
3.7 
5. 9 
8.2 
7. 8 
8.0 
7.7 
6. 8 
6.6 
7.6 
6.6 
2.5 
3.5 
5 
3.5 
2 
3 
6 
8 
8 10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
-a; 
TABLE B 
HEMATOCRIT, AVERAGE VALUE$ WITH STANDARD DEVIATIONS AND NUMBERS IN DIFFERENT TREATMENT GROUPS; AVERAGES ARE EXPRESSED AS PERCENTAGES 
Of NORMAL VALUE (50%) FOUND IN UNTREATED RATS 
untreated 
' 
2 100.5 
3 90.5 
4 92 .o 
5 95.5 
6 94.0 
7 92.0 
a ?o.o 
9 97.0 
\0 96 .o 
11 102.0 
12 96.5 
13 99.5 
14 93 .s 
15 94.5 
16 97.0 
17 97.0 
18 101.0 
19 95 .0 
20 103 .o 
' 
99.0 
1.9 4 92.0 
5.7 4 102.0 
7.4 4 93.0 
2.5 4 96.5 
3,6 4 86.5 
o.o 4 92.5 
2.' 
2.0 4 95.0 
2.3 
2.8 4 97.5 
2.5 
3 ·' 101 .5 
... 
4.1 4 105.0 
3.< 
3.8 4 100.0 
1.4 2 103.0 
4,2 2 106.0 
7.0 2 107.0 
eontroh, unilateral nephrectomy 
lm 4mg/kg lm 2/Pred 4 AlGI ALG ll ALG 1/lm 4 
. 154 
9 380 
5 .656 
12. 806 
12.476 
8.698 
6.403 
2.58\ 
8.386 
4' 434 
' 
96.0 
97.5 
91 .5 
88.0 
84 .5 
96.5 
95 .5 
96.5 
97.0 
100.5 
101 .0 
97.5 
101 .0 
2.581 4 103.5 
o.ooo 2 106.0 
I ,414 2 96.0 
2 828 2 97.0 
1.414 2 101.0 
o.o 
u 
7.5 
18.0 
14.2 
4.7 
7.1 
6.6 
5.0 
1 . 9 
.o 
.9 
' 
101 .0 7.3 
94.5 3.0 
96.5 1·. 0 
95.5 1.9 
98.0 4.6 
94.0 \0.8 
91 .o 15.3 
97.0 4.2 
92.0 12.3 
98.0 4.3 
' ' 
4 102.0 2.0 3 101.0 
4 99.3 4.1 3 99.0 
76.0 20.4 4 87 
76.0 20.4 4 91.0 
83.0 11.8 4 93.0 
67.5 3.4 4 89.0 
92.0 4.8 4 89.5 
2 98.5 1.0 4 92.0 
100.0 1 .6 
102.0 I .6 4 98.0 
102.5 5.2 
101 .5 100.0 
34 4 97.5 6.6 4 105 
3.' 
3 .3 
2.5 4 95.5 \2.7 
89.0 7.0 
2.8 2 94.0 0.0 
0.0 2 93.0 7.0 
4.2 2 97.0 4.2 
1.4 2 89.0 15.5 
96 0 o.o 
94.0 4.6 
94.0 5.2 
94.0 5. 1 
98.0 2.8 
99.0 4.2 
98.0 o.o 
101 .0 
I 02.5 
100.0 
99.0 
99.0 
99.0 
1.1 
2.5 
18.4 4 
7.5 
1.1 
8. 0 
9. 2 
8.' 
4. 0 4 
1.6 
3.' 
5. 2 
0.0 
4 .. 2 
... 
7.0 
hografh 
untreated 
' 
100.8 
101.6 
75 .a 
79.2 
71.0 
81.0 
85 .6 
86.0 
87 .0 
88.4 
90.6 
91.6 
95 .0 
94.2 
97.5 
93.4 
95.6 
98.4 
95 .6 
93 .6 
.9 
lO 
5. 2 10 
4. 9 10 
11.1 10 
5. 9 \0 
5. 8 10 
I 0. 5 10 
7 .7 10 
6,3 10 
9. 4 10 
6. 8 10 
7. 4 10 
6.8 10 
9.5 9 
7.9 10 
6.5 
1.6 5 
4. 3 5 
3. 8 5 
ollogrofh 
untreated 
' 
101.0 
I 00.2 
69.4 
62.6 
46.8 
48.6 
.., 
u 
12.0 
6.1 
II , 7 
13.3 
lO 
lO 
lO 
lO 
9 
3 6 
lO 
ll 
l2 
l3 
" l5 
l6 
l7 
l8 
l9 
20 
-s 
lm 4mg/kg 
' 
100.6 
96.8 
71.7 
4 70.0 
5 58.5 
6 59.0 
66.6 
73.3 
9 65.3 
10 68.6 
II 66.0 
12 77' 3 
13 67.3 
14 77.3 
15 74,6 
16 74,6 
17 78.0 
18 62 .o 
19 36.0 
20 
.6 
7.3 
8.2 
6.9 
15.2 
19.7 
4.6 
14.0 
20.0 
14.0 
15 '8 
11.3 
\7 .o 
1.1 
3.0 
4.1 
0.0 
0.0 
0.0 
6 101 ,4 
9 101 .5 
9 72,6 
65 .o 
57.6 
6 51 .4 
50.0 
3 60.0 
59.6 
65 ,6 
3 75.3 
3 76.3 
3 76.6 
75.6 
3 77' 3 
3 75.6 
76 .o 
87,3 
82' 0 
84' 6 
1m2 
2. 9 
2 .5 
8.6 
7. 9 
10.7 
13.9 
13 .o 
9.2 
12,6 
16.8 
7.5 
II. 1 
\4,4 
9.5 
7.4 
12 '7 
0.0 
6.4 
5.2 
4.1 
lm 2 pretreated 
0 
' 
10 101.0 
12 98.4 
13 70' 8 
12 63' 2 
10 50.6 
53.6 
51.6 
6 52.0 
6 58.0 
58.5 
6 63.0 
6 69.0 
6 63 .0 
6 68.5 
6 67.5 
5 71 .5 
63,3 
3 61 .o 
3 60.0 
3. 4 
3. 3 
8. 4 
I 8. 2 
16.9 
8. 4 
21.4 
12,5 
15.4 
17.0 
15.0 
15. I 
16.3 
17.5 
15.6 
14.4 
15 '2 
4. 2 
0.0 
lm 2/Pred 4 
' 
10 99.4 
10 100.6 
10 72.8 
10 62.4 
10 61.5 
5 67.7 
5 68.7 
73.5 
4 so' 2 
83.0 
4 S3. 2 
4 83 .0 
S4 .0 
so' 2 
80.7 
4 81 '2 
3 90.6 
94,6 
95.3 
91.3 
3.7 
3 .6 
14.7 
17.3 
11.1 
10.8 
16.4 
15.3 
10.1 
8.1 
7. 9 
6. 8 
9.9 
16.0 
11.1 
14.5 
10.0 
4.1 
9. 4 
7 .o 
a II a gr oft s 
' 
7 100.3 
10 93.7 
10 7\ .4 
10 79' 4 
9 72 .o 
70.5 
75' 1 
s 74.8 
s so .o 
S2 .2 
83.4 
84.2 
8 so.o 
8 84.2 
8 85.4 
88.2 
3 S8,4 
3 89.3 
3 88.6 
88.6 
ALGI ALG ll 
' 
4.0 6 101.2 3.0 
7.6 7 99.4 2.5 
6.3 7 63.7 9.6 
4.5 7 59.1 21.3 
10.4 7 5S.8 16.4 
18.9 7 70.4 14.1 
22.7 7 75.2 7.1 
17.9 7 77.2 5.7 
11.1 7 76.4 9.9 
7.9 7 76.0 8.9 
10.0 7 69.6 18.8 
5.3 7 69.2 15.4 
13.9 7 70.8 14.0 
10.4 7 74.4 9.2 
6.5 7 76.0 12.5 
3.9 7 76.8 15.0 
3.2 5 76.0 17.0 
2.3 3 80.6 14.7 
4.1 3 81.3 22.0 
6.1 71.3 24.1 
ALG 1/lm 4 
' 
96.4 
96.S 
71.2 
66.8 
7 73.2 
5 74.0 
5 77.5 
5 62.5 
5 64.0 
5 63'.5 
5 66.0 
5 85.5 
5 89 .o 
5 90.0 
5 89 .o 
5 94.5 
89.3 
90.0 
90.0 
89.0 
2 .9 
5.4 
6.4 
6.4 
8.3 
I 0.4 
10.6 
5.5 
2. 8 
5.2 
6.7 
10.5 
5 .2. 
2.8 
2.0 
7.5 
8.0 
11.3 
5.6 
7.0 
ALG 11/lm 4 
' 
\01.0 
96.0 
5 69.6 
5 62.0 
5 55.5 
56.0 
66.0 
64 .o 
64.6 
80.6 
60.6 
4 82 .o 
4 80.0 
4 86 .o 
4 S3' 3 
4 82.6 
1.1 
4. 2 
3.8 
13.9 
\9.3 
16.8 
5.2 
19.0 
13.0 
15.2 
16.1 
17,4 
21.1 
14.4 
9. 8 
3.3 
4. 2 
5.6 
7.0 
0 
ALG 11/lm 2 
' 
100.5 
5 101.0 
5 74.2 
5 66.0 
70.7 
4 70.5 
3 74.5 
3 74.5 
3 72.7 
3 7\.7 
3 73' 7 
3 73.7 
3 76.0 
3 77.2 
3 80.5 
3 82.7 
2 68.0 
90.5 
2 91 .5 
3.9 
3.0 
6.5 
7. 3 
7. 7 
5. 4 
9.3 
9. 4 
10.9 
13.7 
12.0 
10.0 
13' 8 
14.1 
13.7 
\1.9 
11.4 
5. 7 
3 .4 
0 
1 
8 2 
8 3 
8 4 
8 5 
8 6 
' 
' ' 
' 9 
' 10 
" 
' " 
' 13 
' 14 
' " 
' " 4 17 
4 " 
4 19 
91.0 
92.0 
93.0 
95 .o 1.4 2 93.0 6.2 4 20 
-~ 
TABlf C 
BlOOD UREA, AVERAGE VALUES WITH STANDARD DEVIATIONS AND NUMBERS IN DIFFERENT TREATMENT GROUPS; AVERAGES ARE EXPRESSED AS PERCENTAGES OF 
NORMAl VALUE FOUND IN UNTREAT_ED RATS (100% = 60 mg% blood urea) 
uotreoted 
' 
2 115.0 
3 116.6 
4 113.7 
5 88. 7 
6 131 . 2 
7 70.0 
8 103.7 
9 86.2 
10 105.0 
II 
12 97,$ 
13 88. 7 
" 
91.2 
0.0 I 117.5 
5.7 3 115.0 
11.0 4 120.0 
8.5 4 106.2 
27.1 4 118.7 
10.6 4 96.2 
6.5 
6.2 4 98.7 
7 .o 
81.2 
'·' 6,2 4 71.2 
14 \\8.7 13.7 
IS 85.0 4.0 4 111.2 
16 10\.2 9.4 
17 87.5 8.6 4 90.0 
18 77.5 3,5 2 115.0 
19 65.0 28.2 2 107.5 
20 87.5 38.8 2 137.5 
lm 4mg/kg 
'. 2 
11 .9 
10.8 
26.4 
19.3 
7.5 
18.8 
20.5 
\1.0 
4.7 
'.2 
35.3 
0.0 
3.5 
3.5 
" 
eonlroh, unlloterol nephrectomy 
lm 2/Pred 4 
' 
113.7 
103.7 
120.0 
90 .o 
110.0 
111.2 
166.2 
113.7 
JOB. 7 
125 .o 
126.2 
133.7 
93.7 
133.7 
115.0 
97 .s 
67.5 
97.5 
19.7 
10.3 
28.2 
10.8 
7. 0 
14.9 
'. 2 
11.0 
25.6 
16.8 
23.9 
2.5 
7 .5' 
1< 
95.0 
98.7 
96.2 
110.0 
86.2 
101 .2 
95.0 
100.0 
116.2 
96.2 
97.5 
6.2 4 67.5 
115.0 
0.0 2 92.5 
3.5 2 105.0 
3.5 2 177.5 
3.5 2 120.0 
ALGI 
31.8 
13' 1 
4.7 
9.1 
10.3 
22' 1 
5.7 
0.0 
6.5 
22.8 
21.7 
' 
110.0 
90 .o 
1 08.7 
110.0 
107 .s 
96.2 
91.2 
115 .o 
112 .s 
127.5 
148' 7 
82.5 
113' 7 
15.0 4 111.2 
o.o 1 107.5 
60. I 2 108.7 
0.0 2 102.5 
88.3 2 105.0 
26.2 2 65.0 
ALG II 
22.9 
10.8 
19.3 
24.1 
22.5 
6.5 
7.5 
7. 0 
18.9 
IS. 5 
8. 5 
'·' 4.7 
2.5 
3. 5 
2.5 
10.6 
0.0 
0.0 
ALG 1/lm 4 
' 
126.2 
106' 2 
116.7 
160.0 
77.5 
101 '2 
63' 7 
96.7 
105.0 
117.5 
96.2 
123. 7 
115.0 
115 .o 
132.5 
60.0 
"' 
13.1 
11.0 
24 .I 
20.6 
13 '7 
8.5 
11 .o 4 
7 .o 
9.5 
4.7 
4 7 
14. I 
7 0 
17.6 2 
7.0 
h?grofh 
vntreoled 
' 
102.5 
126.0 
456.0 
209 .5 
120.5 
147.0 
119.5 
124.3 
109.4 
124.0 
122.5 
122 .o 
110.5 
121.6 
113' 3 
104 .0 
112 .o 
114.0 
103.0 
97 .o 
13.322 6 
40.674 10 
154.240 10 
247.940 10 
34. Ill 10 
126.760 10 
28.230 10 
36.096 6 
25.055 9 
39.355 10 
15.500 10 
19' 321 10 
14.23010 
47.236 9 
18.618 6 
16' 124 10 
27.294 
5.477 5 
24.899 5 
9.082 
ollogrofll 
vnlreoted 
' 
103.5 
114.5 
408.5 
647 .5 
906.1 
838.3 
21.7 
21 .2 
257.2 
262 .2 
253' 0 
260.0 
10 
10 
10 3 
10 
9 
6 
9 
10 
II 
12 
13 
14 
15 
" 17 
16 
19 
20 
lm 4mg/kg 
' 
110.8 
2 101.8 
3 468.3 
4 472.5 
5 610.6 
6 660.8 
7633,3 
8425.0 
9 398.3 
10 420.0 
II 430.0 
12 468.3 
13 391 .6 
14 335.0 
15 416,6 
16 366.6 
17 515 .o 
18540.0 
191000.0 
20 
-g 
' 
32.0 6 102.2 
13.0 8 85.5 
?66.0 9 440.0 
272.1 8 576.2 
300.5 8 645.0 
287.9 ~ 364.1 
282.2 3 458.5 
132,5 3 309.1 
107.7 3 305.0 
54.0 3 321.6 
72,6 3 273.3 
145.0 3 280.0 
52.5 3 284.0 
82.6 3 312.5 
58.5 3 308.3 
161.2 3 322.0 
0.0 I 225.0 
0.0 1 173.3 
0.0 I 225.0 
198.3 
lm 2 
25 .6 
23.2 
304' 3 
285.3 
348.7 
157.3 
322.3 
162.9 
151.9 
184.5 
173.1 
188.9 
158.5 
181 . 4 
185.8 
250.9 
0.0 
27.5 
113. I 
119.3 
lm 2 preheated lm 2/Pred 4 
' 
9 103.7 
10 99.4 
13 505.6 
12 467.5 
10 580.5 
6 216.2 
445.0 
6 420.0 
6 547.5 
6 465.0 
6 480.0 
5 508.7 
23.5 
12' 6 
244' 4 
153.8 
338 .o 
29.2 
338. 7 
131.3 
24.7 
165.3 
\51 .0 
131,6 
417.5. 143.1 
6 451.2 163.7 
6 431.2 165.5 
5 452.5 140.5 
l 558.3 205.9 
3 557.5 123.7 
750.0 176.7 
3 
' 
8 I 09.2 
9 92.5 
8 285.0 
10 442.5 
10 397.2 
303.7 
5 235.6 
239.3 
2 260.0 
251 . 2 
271.8 
231.4 
268.5 
241 . 8 
4 261.2 
262.5 
170.0 
162.5 
163.3 
166.6 
20.7 
14.5 
153' 4 
239.7 
304.7 
174' 0 
69.3 
58.4 
86.8 
101 .5 
113.7 
106.2 
84.9 
104.9 
115.7 
118.1 
229 
31.8 
44 ' 
23 .o 
o II ogrofts 
0 
' 
7 97.8 
10 94 .o 
10 550.7 
10 157.5 
9 130.8 
147.8 
143.5 
130. 7 
8 125.0 
8 155.8 
211.4 
\62. 1 
151 . 4 
8 136.4 
130.7 
8 140.0 
3 128.0 
\17.5 
3 120.0 
3 131.6 
ALG 1 
18.2 
23.8 
286.7 
79. I 
30.4 
21.5 
26.8 
12.3 
17 
52.8 
158.7 
53.2 
33.8 
16.7 
13.6 
21.2 
32.9 
3.5 
18.0 
30.5 
' 
94.0 
5 102.8 
7 470.7 
6 325.7 
6 428.3 
123.7 
7 208.0 
7 211.0 
7 215.0 
6 228.0 
242 .o 
221.0 
218.0 
215 .o 
214 .o 
191 .o 
5 216.2 
251 .6 
326.6 
3 426.6 
ALG ll ALG 1/lm 4 
" 
11.9 5 117.0 
24,\ ·7 105.0 
199.5 
316.8 
443.2 
18.8 
136 8 
124.2 
110. 1 
128,3 
112' 2 
127 .o 
136.9 
134 .4 
157.5 
112.9 
129.6 
210.9 
307.4 
497.7 
456.2 
193.3 
6 179.0 
156.2 
5 157.5 
5 140 .o 
156.2 
5 155.0 
5 137.5 
5 I 26.2 
\47.5 
127.5 
142 .5 
5 130 .o 
123.3 
3 147.5 
3 130.0 
3 135 .0 
46.3 
24.2 
147.2 
85.0 
118.7 
19 
13.2 
47.4 
35 .6 
24..4 
9.5 
29.5 
50.7 
33.0 
18.4 
16.8 
15' 2 
45' 9 
21.2 
35 .3 
ALG 11/lm 4 
' 
5 96.2 
112.0 
4 278.7 
3 309.0 
5 217.5 
255 .o 
253.3 
243,3 
226.6 
246,6 
210.0 
4• 215.0 
250.0 
213.3 
\68.3 
206,6 
135' 0 
120.0 
2 130.0 
2 \37.5 
\7.9 
30.5 
50.0 
196.4 
118.4 
190.3 
161 . 7 
174.8 
163 
164 0 
113 0 
122. 
195.2 
142.6 
88.9 
125.7 
56.5 
28.2 
49.4 
31.8 
ALG 11/lm 2 
' 
85.8 
93. 
4 327' 
5 135.6 
140.0 
164 .3 
290 .o 
307 .I 
3 243. I 
3 187.8 
3 205.6 
3 227.5 
3 223.7 
223.7 
217. I 
219.3 
151 .2 
130 .o 
2 148.7 
127.5 
'.0 
16 .6 
93.8 
30.5 
24. ~ 
57.4 
269.5 
309. I 
134.2 
63' 9 
91.3 
163.4 
147.2 
158.6 
148.4 
149.5 
17 .o 
17' 7 
37'. 0 
24.6 
' 
' 
2 
3 
' 5 
' ' 
' 
' 9 
10 
II 
12 
13 
14 
15 
16 
17 
" 19 
20 
~ 
~ 
0 
TABLE D 
URINE OSMOLAliTY, AVERAGE VALUES WITH STANDARD DEVIATIONS AND NUMBERS IN DIFFERENT TREATMENT GROUPS; AVERAGES ARE EXPRESSED AS 
PERCENTAGES OF NORMAL VALUE FOUND IN UNTREATED RATS (100% = 2190 m01mol/l) 
cootroh, uniloterol nephrectomy 
ul)!reoted lm 4mg/kg lm 2/Pred 4 ALGI ALG 11 ALG 1/lm 4 
' 
2 110.0 
3 120.7 
-4 95' 7 
5 109.7 
6 
7 72.7 
8 108.0 
9 82.5 
10 90.3 
I. 4 
4 .I 
8.6 
2.6 
' 
108.5 
122.5 
127.0 
114.0 
114.2 
110.7 
9.5 4 105.0 
0.0 
10.9 4 101.2 
1.5 
11 96.2 26.8 4 110.5 
12 88.0 6.7 
13110.0 10.6 4 102.7 
14102.5 3.4 4 
6.3 
9.8 
97.0 15 95.5 
16 104.6 
17 98.3 
18 71.0 
6.6 3 71.0 
11.3 2 82.0 
19 96.0 12.7 
20 91.5 0.7 
97.5 
86.5 
' 
2, I 2 117.7 
4.9 2 103.3 
0.0 I 96.5 
5.7 4 70.0 
9.2 4 82.2 
11.5 4 111.0 
14.9 
2.6 
117.5 
125.2 
116.3 
117.0 
' 
6.9 4 103.7 
6.4 3 106.0 
10.6 4 95.0 
23.8 3 116.0 
27.9 4 85.0 
11.4 4 91.5 
' 
10.6 4 97.0 
6.5 3 107.6 
21.8 4 93.7 
24.0 3 99.6 
32.1 3 84.5 
13.0 4 88.0 
0 
' 
7.0 2 122.2 
10.0 3 119.5 
10.0 4 106.6 
5.5 3 108.5 
4.9 2 88 7 
17.2 4 104.2 
2.1 2 89.2 6.1 4 89.0 14.1 2 58.7 
8.3 4 106.0 7.0 2 97.0 19.2 99.6 
8.6 3 89.2 28.6 4 81L7 17.6 
11.3 3 108.0 38.1 2 102.7 
5.6 98.5 22.7 94.2 20.6 4 71.7 
86.6 
105.3 29.2 3 59.3 
94.6 
12.4 
110.5 10.1 
9. I 107.0 5.4 
4.8 111 .0 
2.8 2 104.5 
0.0 I 109.0 
6. 4 
6.3 
0.0 
96.7 32.6 
12.2 3 101.2 
17.6 3 
9.6 3 100.0 
lt6.0 6.0 3 89.2 
104.5 20.5 2 92.0 15.0 3 96.5 
96.0 11.3 2 84.5 
3.774 4 
8.962 4 
3.054 3 
10.723 4 
12.311 4 
15. 195 4 
14,682-4 
9.712 3 
7.228 4 
5.377 4 
10.148 3 
5.8524 
7.7782 
0.707 2 
2.1 2 79.0 12.7 66.5 17.6 57.0 25.4 2 95.5 13.435 2 
6.3 2 108.0 0.0 93.5 2. 1 38.0 1.4 2 73.5 0.707 2 
iJogroftf 
untreoted 
' 
93.6 16.9 
Ill. 1 7. 9 
31.8 10.4 
46.8 19.3 
52.3 15.3 
53.5 23.1 
58.3 
60.6 
58.6 
60.2 
22 '9 
27.9 
23.9 
20.6 
57.8 18.0 
64.5 18.7 
67,7 22.2 
59.7 17.4 
6 
7 
5 
8 
8 
8 
10 
9 
10 
9 
9 
8 
58.4 22.5 9 
64,3 19.2 
68.6 23.4 
66.2 28.4 
10 
5 
5 
55.8 21.4 5 
59.2 24.1 5 
allografh 
untreated 
' 
80.5 36,4 
111.0 6.2 
38.0 8.4 
24.0 5.5 
17,6 4.9 
18.5 2 .I 
• 
9 2 
• 3 
6 4 
5 
6 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
-
-
-
lm 4 mQ!kg 
' 
96.6 
2 102.8 
3 41 .7 
31.0 
5 26,6 
6 25.4 
7 20.3 
8 20.3 
9 24.0 
10 22.3 
11 20.0 
12 18.5 
13 20.5 
14 20.6 
15 24.6 
16 19.0 
17 22.0 
18 
19 23.0 
20 
11.7 
15.8 
13.2 
0,6 
12.8 
0.5 
2. 3 
4.5 
3.6 
4.1 
2. 6 
3.5 
0.7 
0.5 
1.5 
o.o 
0.0 
0.0 
0 
' 
94.8 
6 102.6 
35.2 
8 27.4 
5 22.5 
5 24.5 
25.8 
27,6 
27.0 
26.2 
3 29.3 
2 29.8 
2 29.6 
3 32 .o 
28.5 
30.2 
24.0 
29 .o 
25.6 
28.0 
lm 2 lm 2 protreoted 
' 
33.9 9 102.8 
17.4 9 106.1 
15.0 11 45.4 
7.2 s 31.7 
7.0 9 25.7 
6.2 7 31.4 
8.9 7 39.5 
9.6 6 33.3 
9,6 5 26.2 
9.0 5 28.3 
6.4 5 25.2 
11.2 5 23.2 
7.5 6 27,7 
9.6 5 25.0 
8.1 6 24.5 
9,0 5 18.6 
0.0 1 20.0 
7.0 3 16.0 
4.0 3 18.0 
7.2 
10.6 
10.7 
27 .6 
6.5 
7.7 
5 ,5 
\5.8 
18.9 
\1.2 
13 .s 
\0.5 
'.' 
10.8 
II .4 
\2.5 
1.1 
2.0 
I .4 
o.o 
lm 2/Pred 4 
0 
' 
7 81.7 
6 110.6 
7 41 .3 
25.7 
29.7 
5 33.7 
4 31 '7 
3 32.7 
4 30.8 
3 34.5 
35.7 
36.5 
4 33.5 
39.8 
36.4 
3 33,2 
3 49,0 
47.0 
45.0 
44.3 
24 .I 
23 .4 
11.3 
12.5 
9.6 
7 .5 
'.3 
9.5 
10.3 
11.3 
13.5 
14.2 
12.1 
15.2 
18.0 
13.3 
11.5 
20.4 
1 o. 8 
11.1 
allografts 
' 
103.0 
6 108.7 
6 49 .o 
9 43 .3 
50.6 
46.0 
8 44.8 
7 47.1 
52.4 
8 51' 7 
54.6 
8 50.5 
50.1 
49.4 
47.5 
8 54.0 
3 52.4 
3 43.6 
3 43.0 
42.6 
ALGI 
' 
17.0 5 93.0 
13.3 4 100.7 
32.5 2 27 .o 
15.7 6 29.4 
11.7 5 37.4 
14.8 5 49.5 
13.1 7 39.0 
10.3 7 39.0 
15.9 7 35.0 
19.0 7 41.8 
23.4 6 41.6 
18.5 7 38.2 
20.0 7 41.6 
17.3 7 43.2 
15.8 7 49.5 
18.3 6 44.4 
18.9 5 46.0 
18.7 3 48.3 
\5.1 3 37.0 
11.2 3 47.6 
ALG II ALG 1/lm 4 ALG 11/lm 4 
' 
ALG 11/lm 2 
' 
21.2 2 107.2 
14.8 7 121.5 
8.2 4 39.5 
13,3 5 34.6 
13.9 7 60.4 
14.0 4 62.2 
22.7 4 58.0 
17.0 5 59.6 
15.8 4 65.5 
12.6 5 66.6 
16.3 5 62.5 
15.8 4 62.0 
21.0 3 57.5 
19.5 5 62.7 
20.5 4 59.0 
22.4 5 61.7 
16.6 3 54.5 
25.6 3 60.5 
15,7 3 57.0 
28.0 3 52 .o 
' 
6.0 5 103.6 6.0 3 103.0 
4.2 4 101.6 11.2 3 101.0 
10.7 4 41.6 8.1 3 45.1 
10.8 5 35.2 26.7 4 54.7 
16.2 5 37.0 7.2 3 39.1 
19.6 4 45.3 24.3 3 38.8 
20.2 4 39.0 28.7 3 34.2 
14.5 3 37.6 25.4 3 37.8 
18.2 4 40.3 30.8 3 34.5 
18.9 3 37.3 23.1 3 29.5 
19.0 4 41.3 27.4 3 31.1 
5.1 3 25.0 o.o 1 33.3 
20.0 4 39.0 21.7 3 29.0 
16.8 4 43.3 30.8 3 32.4 
11.8 4 45.0 32.9 3 31.1 
10.5 4 40.3 26.5 3 32.8 
12.0 2 51.0 35.3 2 36.7 
\3,4 2 50.5 34.6 2 39.5 
7.0 2 49.0 32.5 2 36.0 
2.a 2 39.0 15.5 2 42.5 
0 
10.3 7 1 
1o.o a 
17.4 7 3 
27.3 8 
10.6 7 5 
13' 7 5 6 
12. o a 7 
12.3 6 a 
14.4 7 9 
8.2 8 10 
16.3 7 11 
15.2 a 12 
6.a 7 13 
11.5 7 14 
11.7 6 15 
13' 8 7 16 
12.9 4 17 
15. 1 4 1 a 
15.6 3 19 
17' 1 4 20 
-TABLE E 
-N URINE PRODUCTION PER 24 HOURS, AVERAGE VALUES WITH STANDARD DEVIATIONS AND NUM8£RS IN DIFFERENT TREATMENT GROUPS; AVERAGES ARE EXPRESSED AS 
PERCENTAGES Of NORMAL VALUES FOUND IN UNTREATED RATS (100%" 5 ml) 
o::onlroh, vnllateral nephreelomy lsogrohs 
uotreoted vnlreoted lm 4mg/kg lm 2/Pred 4 ALGI 
' 
2 80.0 
3 105.0 
4 95 .0 
5 87.5 
6 n.s 
75.0 
8 87.5 
9 95.0 
10 9-0.0 
11 90.0 
0 
' 
27.0 4 90.0 
20.8 4 90.0 
19.1 4 90.0 
22.1 4 72.5 
15.0 4 72,5 
17.3 4 1\0.0 
22.1 4 105.0 
7.0 2 85.0 
14,1 2 80.0 
42.4 2 80.0 
0 
14. 1 
25.8 4 
8.1 
' 
25.0 4 97.5 
9.5 4 106.6 
25.8 4 127.5 
7.0 2 122.5 
7.0 2 145.0 
14.1 2 120.0 
28.2 2 110.0 
0 
" 
220.0 226.2 
155.0 95.7 
137.5 33.0 
17.0 4 172.5 89.9 
11.5 3 100.0 46.9 
25.0 4 155.0 99.8 
33.0 4 150.0 38,2 
21.2 2 120.0 70.7 
28.2 2 140.0 113. 
14.1 2 160.0 84.8 
lm 4mg/kg lm 2 lm 2 pretreated lm 2/Pred 4 
262 .0 
260.0 
4 480.0 
5 666.6 
6 656.6 
7 633.3 
510.0 
9 
10 360.0 
II 460.0 
73.3 23.0 3 
15'4,3 5 232.3 160.4 
219.0 4 325.5 218.9 
226.2 2 357.1 214.2 
195.0 3 383.3 181.6 
40.4 3 375.0 238.8 
227.4 3 355.0 146.7 
115.3 3 326,6 157.9 
410.0 236.4 
0.0 I 356.6 212.2 
0.0 I 403.3 127.4 
13 295.0 
9 227.0 
378.0 
6 527.5 
6 470.0 
6 577.5 
6 422,5 
560.0 
3 640.0 
3 
70.1 
184.3 
138.6 
270.4 
231.2 
142' 4 
156.7 
84.8 
28.2 
162.0 99,5 
10 366.6 125.0 
5 348.7 97.8 
367.5 157.0 
377.5 162.8 
382.5 282.5 
347.5 231.3 
160.0 72. 
210.0 52.9 
185.0. 35.3 
0 
' 
ALG II AlG 1/lm 4 
" 
25.8 4 112.5 
22.1 4 107.5 
23,8 4 95.0 
14.1 4 77,5 
8.1 4 90.0 
12.5 
55 .0 
41.2 
25 .o 
25 ' 
25. I 
77 
"· 14. 1 
0 
' 
70.0 
82,5 
105.0 
80.0 
80.0 
125' 0 
132.5 
220 .o 
225.0 
285.0 
33. I 4 95.0 
61 .a 4 130.0 
42.4 2 80.0 
7.0 2 90.0 
35.3 2 110.0 28.2 2 
86.6 
263.3 
188.7 
317 .I 
181 .o 
178.0 
171 .0 
153 .o 
138.0 
166 .o 
147.5 
o II o g r oft s 
AtG 1 
5 237.5 
236,6 
232,5 
268.3 
8 305 '7 
237. I 
8 151.6 
3 256.6 
270.0 
210.0 
224.8 
82' 1 
68.9 
225.9 
272.5 
215,6 
67.0 
120.5 
151.3 
110.0 
AtG II 
110.000 0.0 
282.8 
6 158.3 
292.0 
6 326.0 
308.0 
302' 0 
6 368.0 
303.3 
356,6 
303.3 
181.9 
109.8 
177 
202.4 
160' 2 
156. I 
194.6 
291 ,6 
232' 4 
292.6 
AlG 1/lm 4 
130.0 
7 266.0 
6 207.5 
235.0 
170.0 
102' 5 
5 155.0 
147.5 
3 105.0 
75.0 
180.0 
14. I 
79.8 
133.0 
114.7 
34.6 
41.9 
46.5 
42.7 
35.3 
35' 3 
42' 4 
23.0 3 
160.3 6 
74.9 8 
323.6 7 
93.9 10 
61 .0 10 
64.0 10 
38.0 10 
34.9 5 
80 
71 . a 
AtG 11/lm 4 
358.0 
236.6 
440.0 
396.6 
396,6 
390 .o 
323.3 
265.0 
305.0 
375.0 
127.3 
155.3 
253.5 
256.9 
236' 2 
1 so. 2 
180.0 
190.9 
233.3 
275' 7 
ollogrofh 
untreoted 
' 
95.0 
271 .1 
210.0 
21.2 
135.6 
229.6 
ALG 11/lm 2 
100.0 
260.0 
3 223' 7 
312.5 
395 .0 
441 .2 
3 365.0 
295 '7 
307.5 
332.5 
267.5 
0.0 
196.1 
107' 1 
116.9 
190.7 
212 9 
153.9 
100.4 
149.5 
206.2 
128.4 
0 
' 
9 ' 
• 3 
' 
' 
' 
9 
10 
11 
' 7 
8 
10 
11 
~ 
~ 
w 
TABLE F 
BLOOD PRESSURE, AVERAGE VALUES WITH STANDARD DEVIATIONS AND NUMBERS IN DIFFERENT TREATMENT GROUPS; AVERAGES ARf fXPRESSED IN mm Hg 
(normol blood preuure, found In untreated roh is 125 mm Hg) 
unlteoted 
' 
127.5 8.6 
137:5 1\.9 
4 135. 0 
5 137' 5 
6 141.2 
7 138.7 
8 121.2 
9 145.0 
10 137.5 
II 130.0 
10.0 
6 .• 
6. 2 
4.7 
9 .• 
7.0 
3.5 
o. 0 
lm 4mg/kg 
127.5 3.5 
2 112.5 3.5 
3 
5 
6 170.0 0.0 
7 180.0 26.4 
8 200.0 
9 230.0 
10 160.0 
11 
0.0 
0.0 
0.0 
eontrols, unilateral nephreetomy 
lm 4mg/kg lm 2/Pred 4 
' 
\33. 7 
140.0 
141. 2 
\41.6 
ISO. 0 
145.0 
150.0 
160.0 
9,. 
13.2 
4.7 4 
' 
7.6 3 136.6 5.7 
14.1 2 150-0 15.0 
o.o l 162.5 3.5 
o.o 2 \65.0 7.0 
o.o 2 147.5 24.7 
lm 2 lm 2 pretreated 
122.2 9.3 9 126,2 4.7 
118.3 7.5 9 101.8 21.7 
130.0 32,1 9 111.6 19.6 
135.7 23.3 7 130.0 27.9 
139.1 57.3 6 145,0 12.9 
140.8 26.0 6 152.5 20.6 
3 150.0 39.3 6 178.7 20.9 
ALGI ALG II 
' 
125. 0 
132.5 
140.0 
143. 7 
143. 3 
\57.5 
152.5 
2 152.5 
' 
120.0 5.0 
125.0 10.8 
137.5 6.4 
o.o 2 123. 
5.0 4 133. 
4.0 4 13\.2 
6.2 4 132.5 
12.5 3 125.0 
10.6 2 127.5 
3.5 
17.6 
7. 5 
20.5 
19.3 
9. 5 
1 o. 8 
10.6 
!m 2/Pred 4 
ollogrofts 
ALGI 
131.2 
126. 
6 146 .6 
166.6 
148.3 
163 .3 
155.0 
6.2 
5 7 
.7 
15.2 
20.2 
15.2 
29 .o 
• 
137.5 
122.5 
3 111.6 
121 .2 
123.0 
120.8 
125.0 22.9 3 173,7 39.8 4 145.0 10.9 6 124.2 
136.6 
3 138.3 
3 135 .o 
5' 5 
10.6 
16.0 
24 .6 
10.9 
13.5 
9,3 
5' 7 
15.2 
5.0 
160.0 42.4 2 185.0 21.2 2 148,3 17.5 
148.3 38.1 3 210.0 0.0 2 158.3 32.5 
162.5 53.0 2 130.0 22.9 
" 
ALG 1/lm 4 
' 
118.3 
141.6 
130.0 
127.5 
128.7 
127.5 
130.0 
152. 5 
130. 0 
2' 8 
2' 8 
I O. 8 
3.5 
8. 5 
15.5 
0. 0 
3' 5 
o.o 
hogrofts 
untreated 
' 
130.0 14.142 2 
107.5 4.1836 
120.0 12.2476 
124. I 
127,5 
129.2 
127.1 
136.6 
127.0 
131 .2 
137.0 
9. 174 6 
14.0536 
7. 867 7 
8.591 7 
9.013 9 
20.796 5 
4. 787 4 
6. 708 5 
ALG ll ALG l/lm 4 ALG ll/lm 4 
123 .0 
104. 1 
121.0 
\40.0 
137 .0 
5 132.5 
6 132 .o 
127 .o 
3 150.0 
3 127.5 
3 130.0 
5. 7 5 
15.9 6 135.0 
18.1 5 111.2 
11.7 5 135.0 
16.4 5 123.3 
13.2 4 126.2 
17.5 5 126.2 
\4.4 
30.0 
10.6 
0.0 
5 131 . 2 
3 142.5 
2 \52.5 
132.5 
0. 0 
29.5 
12.9 
20 .2 
16.5 
21 .3 
22 .5 
31.8 
10.6 
24.7 
130.0 
I 02.5 
100.0 
123.3 
132.5 
\30.0 
133.3 
4 142 .5 
135 .o 
127.5 
2 J40.0 
8.6 
\1.9 
18.7 
15.2 
17.6 
o.o 
7,6 
3.5 
o.o 
17.6 
14.1 
allogrofh 
unlleoted 
' 
133.7 4.7 
\13' 3 11 .5 
113.3 20.8 
ALG 11/lm 2 
125 .o 
115 .o 
121 . 8 
136.2 
141 . 8 
149.2 
128.5 
147 .I 
133.3 
133.3 
126.6 
10.6 
16.5 
IS. 1 
20.6 
25.4 
22.0 
19.0 
35.9 
15.2 
10.4 
5.7 
8 
8 
3 
5 
6 
9 
10 
11 
2 
3 
6 
7 
8 
3 9 
10 
11 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
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